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ABSTRACT
Metastatic breast cancer (MBC) is mainly responsible for breast cancer-related
deaths worldwide. MBC is currently untreatable and has a 5-year survival rate of as low
as 26% in patients. Hypoxia has been identified as a driving force for distant metastasis in
breast cancer. Hypoxic response is primarily mediated by hypoxia-inducible factor,
HIF1A which recruits chromatin remodelers and activates target genes directly or via
downstream effector transcription factors. Several accessory molecules have also been
implicated to be involved in the hypoxic response elicited by tumor cells. In this study,
we focus on two such transcriptional regulators, SMARCE1 and BHLHE40, which play a
pro-metastatic role in breast cancer progression in-vivo.
SMARCE1 is a subunit of the chromatin remodeler complex SWI/SNF which
causes nucleosome remodeling to facilitate expression of target genes. While aberrant
activation of the chromatin-remodeling SWI/SNF complexes has been associated with
cancer development and progression, the role of each subunit in tumor cells is poorly
defined. This study characterizes the role of SMARCE1/BAF57 in regulating metastasis
of breast cancer cells via the PTK2 pathway. SMARCE1-knockdown reduced lung
metastasis of breast cancer cells and sensitized tumor cells to anoikis. In response to loss
of attachment, SMARCE1 is shown to interact with and potentiate transcriptional activity
of HIF1A, resulting in rapid PTK2 activation. Both HIF1A and PTK2 were indispensable
for SMARCE1-mediated protection against anoikis by promoting activation of MAPK
and AKT pathways while suppressing expression of pro-apoptotic BIM protein.
Expression data analysis of a large cohort of human breast tumors revealed high
expression of SMARCE1 or PTK2 is associated with poor prognosis and tumor relapse,
and PTK2 expression is positively correlated with SMARCE1 expression in basal-like
and luminal B subtypes of breast tumors.
BHLHE40 is a validated target of HIF1A and its expression level is correlated
with breast cancer grade and progression in patients. However, its exact role in the
metastatic process is unclear. Here we reveal a novel role of BHLHE40 in regulating
hypoxia-induced secretion of HBEGF to promote tumor cell growth and metastasis.
BHLHE40 knockdown significantly reduced primary tumor growth and lung metastasis
in orthotopic xenograft and experimental metastasis models of breast cancer. Gene
expression analysis implicated a role of BHLHE40 in transcriptional activation of
HBEGF, a heparin binding epidermal growth factor. Chromatin immunoprecipitation
(ChIP) and co-immunoprecipitation (CoIP) assays revealed that BHLHE40 induces
HBEGF transcription by blocking DNA binding of HDAC1 and HDAC2. Cell-based
assays showed that HBEGF is secreted through exosomes and acts to promote cell
survival and migration. Public database provided evidence linking high expression of
BHLHE40 and HBEGF to poor prognosis of triple negative breast cancer.
In summary, this study focused on two novel pro-metastatic mechanisms
employed by HIF1A in breast cancer cells, which can be manipulated to target and
modulate metastatic breast cancer therapeutically. While SMARCE1 plays an essential
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role in breast cancer metastasis by protecting cells against anoikis through the
HIF1A/PTK2 pathway, BHLHE40 increases metastatic potential by regulating exosomal
secretion of HBEGF, which promotes breast cancer cell survival and migration.
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CHAPTER 1.

INTRODUCTION

Introduction
Metastasis is defined as the development of secondary malignant lesions distant
from the primary site of origin. Breast cancer commonly metastasizes to the lung, liver,
bones, and brain. Clinically metastatic breast cancer, known as stage IV (advanced stage)
or recurrent cancer is responsible for 90% of metastasis-related deaths and currently does
not have a cure [1]. Statistically, the National Cancer Institute predicts five-year relative
breast cancer patient survival is as low as 26% in patients detected with stage-IV breast
cancer as opposed to 99% in patients detected with stage-I breast cancer (Figure 1-1) [2].
Therefore, research has been strife [3] in this arena of metastatic breast cancer to find
novel avenues for therapeutic intervention in patients.
Gene expression profiling has shown that clinical outcomes of patients diagnosed
with breast cancer can be predicted using a signature gene array expression pattern [4, 5].
Specifically, breast tumors that occur by dysregulation of C-K-Ras proto-oncogene
(KRAS) or HIF1A pathway show a higher proclivity for metastatic dissemination [6].
However, most researchers concede that metastasis proceeds in a sequential cascade of
steps during which cells acquire specific characteristics for evading the immune system
and enabling the cells to evade internal and environmental stressors[7]. Metastasis
proceeds in a distinct cascade comprising the following sequence of steps:
•
•
•
•
•

Epithelial-Mesenchymal Transition (EMT), migration and invasion: tumor cells
become locally invasive and migratory and invade the basement membrane
Intravasation: tumor cells enter the lymphatic and blood circulation
Circulation: tumor cells get transported to distant tissues via lymph and blood
flow
Extravasation: tumor cells exit the blood circulation to distant secondary
metastasis sites and may encounter dormancy
Distant metastasis: tumor cells overcome hostile stress in the distant stroma,
reinitiate growth and from micro-metastasis that eventually form macrometastasis.
Prerequisites for Metastasis

Many genes and signaling pathways converge to achieve each of the above-listed
steps, endowing cancer cells with abilities to challenge the defined organization and
established homeostasis of target organ, as shown in Figure 1-2 [8]. While metastatic
sites may be pre-disposed as outlined in the famous “seed and soil” concept proposed by
Stephan Paget [9], prerequisites for the initiation of the metastatic cascade are numerous
and contain key elements such as: the intrinsic tumor-initiating capacity, altered cell
adhesions, loss of cell adhesion, motility, resistance to extracellular death signals and
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Figure 1-1.

Breast cancer metastasis.

A. Breast cancer metastasis sites. Reprinted with permission from National Breast Cancer
Foundation, Inc. (www.nationalbreastcancer.org/metastatic-breast-cancer) B. Breast
cancer case statistics for year 2017. C. 5-year relative survival statistics for 2003-2013
Reprinted with permission from SEER Cancer Stat Facts: Female Breast Cancer,
National Cancer Institute, Bethesda, MD.
(http://seer.cancer.gov/ststfacts/html/breast.html)
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Figure 1-2.

Metastatic cascade and signaling pathways involved.

Reprinted with permission from Xin Jin, Targeting Breast Cancer Metastasis. Breast
Cancer (Auckl), 2015; 9(Suppl 1): 23-34.
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eventual disruption of basement membrane[10]. Various intrinsic and extrinsic factors
such as those listed in Figure 1-3 fueled by genomic and epigenetic instabilities are
activated in each of the stages of the cascade enabling tumor cells to maximize metastatic
potential [10]. Al-Hajj et al., first used fluorescence associated cell sorting experiments
(FACS) to show that a CD44+/CD24-/low isolated cell population were more tumorigenic
than other cell populations obtained from primary human xenograft tumors [11]. Since
that integral discovery, many researchers have focused on the identification of markers
linked with tumor initiation capacity. The evidence of self-renewal of a small subset of
tumor cells is minimal and yet to fully elucidated. However, this property is considered
an essential pre-requisite to initiate metastasis [10]. Metastatic cells also lose intercellular
adhesiveness molecularly explained by the loss of CDH1 (E-cadherin) and gain of CDH2
(N-cadherin), leading to EMT. Following the loss of adhesion, metastatic cells gain
motility via the upregulation of growth factor pathways. In MDA-MB-231, upregulation
of epidermal growth factor receptors (EGFR) leads to increased invasiveness and cell
motility, as shown in Matrigel-based invasion assays and scratch wound assays [12].
Evasion of apoptotic signals encountered by the metastatic cells which are generated by
environmental stressors such as loss of adhesion, low nutrients, hypoxia and immune
surveillance; is another vital prerequisite for metastatic cells [13]. Not only do metastatic
cells evade immune surveillance but also manage to upregulate the secretion of a variety
of matrix metalloproteases (MMP’s), which enable cells to invade the basement
membrane, a key process required to form an overt metastatic lesion [14].
Following intravasation, a whole new set of challenges and difficulty awaits a
migratory cell. Hypoxia-activated matrix metalloproteases help in breaching the
basement membrane as discussed above and cancer-associated fibroblasts have been
implicated in the production of pro-metastatic cytokines like CXC motif chemokine
ligand 12 (CXCL12), which facilitates intravasation, anoikis resistance and extravasation
of cancer cells to distant organs [15, 16]. The pattern of colonization can be defined by
the seed and soil concept proposed by Paget. Once extravasation has occurred, cancer
cells may enter a state of dormancy, but eventually the cell must overcome this state in
order to generate overt metastatic lesions [17]. Several mechanisms are involved in
surmounting this dormancy, which are specific to the secondary organ being colonized.
For example, production of colony stimulating factor (CSF1), tumor necrosis factor
ligand (TNFSF11), and interleukins (IL6, IL8, IL11) are essential for successful
colonization of tumor cells in bones [10].
Role of Tumor Hypoxia in Metastasis
Tumor hypoxia is a dynamic condition that results in heterogeneity in tumor cell
population and contributes to overall aggressiveness of the tumor [18]. Rapid utilization
of oxygen and nutrients by the actively dividing tumor cells in solid tumors leads to the
generation of hypoxia pockets and low nutrient availability, which is worsened by
structurally and functionally abnormal vessels that form within solid tumors [19]. One
way of measuring oxygen levels in tissue is by using electrodes to measure the partial
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Figure 1-3.

Cell intrinsic and extrinsic pressures that drive metastasis.

Reprinted with permission from Joan Massague, Cancer Metastasis: Building a
Framework. Cell, Volume 127, Issue 4, p679-659, November 2006.
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pressure of oxygen (pO2). The median pO2 in healthy human breast tissue is 65mm of
Hg, and by contrast breast cancer tissues have a median pO2 of 10mm of Hg [20]. pO2 of
less than 10 mm Hg has been linked to increased metastasis in breast cancer [21]. One
explanation offered for this phenomenon is that intratumoral hypoxia acts as a
pathological stimulus, driving changes in gene expression leading to aberrant gene
expression patterns contributing to a metastatic phenotype. In primary tumor cells, for
instance, hypoxia upregulates the expression of CXC motif chemokine receptor (CXCR4)
which leads to an increase in the migratory and invasive phenotype of MDA-MB-231 and
MCF-7 cells lines [22]. Tumor cells have been noted to employ multiple strategies to
overcome the hypoxia stress, becoming remarkably tolerant to hypoxia stress [23].
However, prolonged hypoxia or nutrient deprivation leads to necrotic cell death, which
are found in solid breast tumors. Hypoxia of primary tumors have also been shown to
trigger systemic release of molecules such as angiopoietin like protein 4 (ANGPTL4) and
lysyl oxidase (LOX) which prime the metastatic niches for subsequent colonization of
metastatic breast cancer cells [24, 25].
Listed below are known mechanisms used by hypoxic stress to modulate
metastatic potential:
•

Cytokine secretion – HIF1A regulate secretion of various cytokines which help
promote primary tumor cell migration, angiogenesis, and immune evasion. HIF1A
can activate vascular endothelial growth factor (VEGF) production to promote
angiogenesis, and induces release of C-C motif chemokine ligand 5 (CCL5) and
CXCL12 to recruit myeloid cells which elicit an inflammatory response, and
promote resistance to T-cell mediated death by increasing expression of
programmed death-ligand-1 (CD274) on tumor cells [26].

•

Extracellular remodeling – Hypoxia can modulate the collagen present in the
extracellular matrix via modulation of LOX family of proteins, they also
upregulate secretion of matrix metalloproteinases that enable degradation of
extracellular matrix (ECM) and aid migration of primary tumor cells [27].

•

Regulation of immune cell infiltration - HIF1A deficient mice show delays in
myeloid cell infiltrations proving the importance of hypoxia in macrophage
recruitment in tumors. These macrophages secrete growth factors and cytokines
such as VEGF, platelet-derived growth factor (PDGF), interleukins, and
transforming growth factor beta (TGFB) which may attract further macrophages,
activate stromal cells and aid in the survival and proliferation of primary tumor
cells [28, 29].

•

Metabolic adaptation – HIF1A mediated upregulation of glycolytic enzymes has
been reported in several studies [30]. In order to maintain a high glycolytic rate,
pyruvate is metabolized rapidly to lactate by HIF1A mediated upregulation of
lactate dehydrogenate enzyme (LDHA) [31]. In conjunction with amplification of
MYC proto-oncogene, HIF1A can also exploit glutamine metabolism which is
also associated with increased aggressiveness of tumor cells [32]. HIF1A has also
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been shown to engage tumor protein 53 (TP53) mediated gene expression in
tumor cells experiencing chronic or prolonged hypoxic stress to overcome
reactive oxygen species (ROS) stress [33, 34].
•

Anoikis resistance – Loss of attachment to basement membrane can cause loss of
survival signals in tumor cells [35]. HIF1A has been shown to upregulate
ANGPTL4 and EGFR pathway, while downregulating BCL2 interacting mediator
of cell death (BCL2L11/BIM), BCL2 modifying factor (BMF), and integrin alpha
subunit - ITGA5, leading to evasion of anoikis (apoptotic pathway initiated in
detachment cells) [36-39].

•

Phenotypic plasticity (EMT/MET) – Rapid phenotypic change from epithelial
to mesenchymal in the primary tumor site of the metastatic niche, plays a key role
in metastasis [40]. Hypoxia has been known to promote EMT through direct
HIF1A mediated transcriptional activation of Twist family basic helix-loop-helix
transcription factor (TWIST) and zinc finger E-box binding protein (ZEB2), and
also suppression of CDH1 [41].

Not only is hypoxia implicated in the increase of metastatic potential of breast
cancer cells but this state has also been linked to chemo- and radio-resistance. This
observation dates to 1953 when Grey et al., showed that sensitivity of tumor cells to Xrays is about three times stronger when irradiated in an oxygenated medium as opposed
to an anoxic medium [42]. Taken together these evidences suggest that hypoxia is an
important multifaceted driver of metastasis, which leads to study of regulators in hypoxia
pathway discussed below.
Hypoxia Inducible Factor HIF1A Drives Metastasis
Hypoxia is sensed by molecular dioxygenases such as prolyl dehydrogenases
(PHD) in cells [43]. These oxidoreductase enzymes modify prolines in the oxygen-labile
subunits of HIF in the presence of oxygen leading to an E3 dependent ubiquitination and
degradation of HIF under average oxygen concentration [44]. In hypoxia, due to an
absence of oxygen, PHD’s are inactive, leading to an increase in HIF activity [45]. HIF
can, directly and indirectly, regulate cellular processes like cell cycle, cell growth,
migration, invasion, autophagy, chemo-resistance, and anoikis-resistance, all of which
may increase the metastatic potential of cancer cells [46]. HIF also regulates chromatin
remodeling through epigenetic modifications, post-translational histone modifications
and DNA methyltransferases [47].
HIF are heterodimers comprising an oxygen-dependent subunit – HIF1-alpha
(HIF1A/ HIF1α) and a constitutively expressed HIF1-beta (HIF1B/ HIF1β) subunits. It is
the HIF1A subunit that contains the oxygen-mediated PHD modifiable proline residues.
Under hypoxia, HIF1A is stabilized, and over 70 downstream direct transcriptional
targets and approximately 1500 indirect downstream HIF targets have been identified till
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date, all of which can help through the metastatic cascade of tumor cells [48] as shown in
Figure 1-4.
HIF1A promotes primary tumor growth and vascularization via direct
upregulation of VEGF and CXCL12. sh-RNA mediated knockdown of HIF1A alone,
may reduce lymph node metastasis, and osteolytic lesions. Conditional knockout of
HIF1A in epithelial cells in MMTV-PyMT mice has been shown to decrease spontaneous
lung metastases by ~50% [49]. During the metastatic cascade, HIF1A promotes EMT,
migration, and invasion through the basement membrane by downregulation of CDH1
and upregulation of SNAI1( Snail family Zinc finger transcription factor), SNAI2,
TWIST, TCF3 (Transcription factor 3), HGF (Hepatocyte growth factor), ITGA5,
ITGA6, MMP2 and MMP9 [50]. Intravasation and extravasation of tumor cells occur via
loosened junctions amongst epithelial cells facilitated by the abnormal structure and
function of tumor-associated blood vessels. VEGFA, VEGFC and (PDGFB), which are
well documented angiogenic factors, are directly upregulated by HIF1A and help in intratumoral vascularization, resulting in poorly constructed vasculature to facilitate
intravasation or extravasation of tumor cells [51]. In addition, HIF1A mediated secretion
of CXCL12 and CCL21(C-C motif chemokine ligand 21) that induce intravasation in
breast cancer cells. Survival in lymphatic or blood circulation requires survival of breast
cancer cells from anoikis, a form of cell death activated by loss of attachment. HIF1 has
been shown to be activated upon loss of attachment and implicated in anoikis resistance
via upregulating the EGFR- MAPK (mitogen activated protein kinase) pro-survival
pathway [52]. Another target of HIF1A, L1 cell adhesion molecule (L1CAM) is a
transmembrane protein which favorably mediates breast cancer cell and epithelial cell
interactions aiding metastatic cells until they reach favorable metastatic niches to
extravasate [50]. Specific cytokines have been shown to impart metastatic tropism to
breast cancer cells. For example, HIF1A mediated expression of ANGPTL4 mediates
tropism to lungs and CXCR4 expression confer tropism to bone [53, 54]. Upregulation of
LOX and MMP’s favorably allow for the formation of overt metastases [55]. It is
proposed that metastatic cells revert back to epithelial phenotype via PHD-mediated
inactivation of HIF in non-hypoxic conditions thus relieving repression of CDH1 [56].
These studies have led to the identification of a variety of drugs that inhibit HIF1 activity
in mice as shown in Figure 1-5 [57].
Activation of HIF1A targets mentioned above could be by direct HIF1A-mediated
transcriptional activation or indirectly via transcriptional factors induced by HIF1A. To
bring about this activation, HIF can recruit chromatin modifying complexes such as
SWI/SNF [58], ISWI [59] and several co-factors like CREB binding protein (CREBBP)
and E1 binding protein 300 (EP300) [48]. Further study shows that regulation of
downstream targets by HIF need a multiprotein complex which includes HIF1A, and the
accessory transcription factor, p300/CREBBP [60, 61]. Sequence analysis of regions
surrounding the functional hypoxia-responsive elements reveal motifs for binding of
other transcription factors such as FOS (Fos proto-oncogene), CREB (cAMP responsive
element binding protein), NYF (nuclear transcription factor), and E2F (Eukaryotic
transcription factor), suggesting a functional interplay amongst DNA binding proteins,
that may modify the hypoxic response [60]. However, this co-factor recruitment and
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Figure 1-4.

Transcriptional targets of HIF.

Seventy direct targets of HIF and the roles they orchestrate in the metastatic cascade.
Reprinted with permission from Joaquin M Espinosa, Transcriptional Regulation by
Hypoxia Inducible Factors. Crit Rev Biochem Mol Bio (HHS Author Manuscripts). 2014
Jan-Feb; 49(1): 1-15.
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Figure 1-5.
pathway.

HIF1A inhibitors modulate different aspects of the HIF1A activation

Reprinted with permission fromWei Li, HIF-1α pathway: role, regulation and
intervention for cancer therapy.Acta Pharm Sin B (Elsevier), 2015 Sep, 5(5): 378-389.
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downstream pathway activation are cell context specific. Not only does the hypoxia
response differ in different cell lines, a comparative study found the induction of HIF
targets genes were higher in epithelial state compared to a mesenchymal state of the same
cell line [48]. To compound its functional complexity, HIF1A may activate secondary
downstream transcription factors like basic helix-loop-helix protein DEC1/ BHLHE40
that help to further orchestrate the hypoxic response [62]. HIF1A, their direct targets,
transcriptional co-regulators, and co-factors, can all contribute to every step of the
metastatic cascade discussed above and impart resistance to immune attack via several
HIF-dependent mechanisms during the metastatic process [29, 50]. Since the hypoxic
response is one of the important drivers of metastasis, identifying the transcriptional coregulators of HIF1A may open doors to novel therapeutic interventions in patients.
Screening for Transcriptional Regulators Involved in Metastasis of Breast Cancer
Cells
Transcription factors are favorably poised to rapidly activate or inactivate gene
expression based on adjacent tumor cells and environmental cues, as shown in Figure 1-6
[63]. Therefore, it comes as no surprise, that transcription factors are often deregulated by
tumor cells to aid with tumor progression and metastasis. Transcription factors can
upregulate or downregulate expression of specific downstream genes upon receiving
signals from 19 key signal transduction pathways [63]. As discussed previously,
development of cancer requires a multiplex reversible phenotype and several nonMendelian epigenetic alterations that may account for mosaic or tissue-specific gene
expression. These features make transcription factors attractive targets for cancer therapy.
Many researchers have now focused their efforts on studying how transcription factors
affect genetic and epigenetic gene expression which aids tumor cell survival and
proliferation, uncovering novel therapeutic targets for a more targeted cancer therapy
[64].
Many environmental cues including hypoxia have been shown to cause epigenetic
modifications in solid tumors. The master hypoxia regulator HIF1A can cause both gene
activation and repression imparting pro-survival ability, anti-apoptotic mechanisms, and
resistance to radiation and chemotherapy in tumor cells, resulting in poor outcome in
patients [65]. Several of these targets such as SNAI1 and TWIST are activated directly by
HIF1A [50], but there are also a multitude of downstream targets whose activation is
facilitated by other downstream transcription factors, epigenetic and chromatin
remodelers, all of which are directly or indirectly influenced by HIF1A [48]. Many such
downstream transcription factors and epigenetic modifiers such as histone methylases,
demethylases, acetylases and chromatin remodelers, have been linked to an aggressive
and malignant phenotype in patients. In this study, we dissect the role of such
transcriptional modulators in metastasis of breast cancer.
BHLHE40/DEC1 is a basic helix loop helix protein reported to be a
transcriptional repressor involved in the regulation of genes associated with circadian
rhythm, apoptosis and differentiation [66]. Immunohistochemical studies show that
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Figure 1-6.

Transcription factor activity.

Simple flow diagram of transcriptional factor mediated pathway activation. Reprinted
with permission from Daniel W Nerbert, Transcription factors and cancer: an overview.
Toxicology (Elsevier), Volumes 181-182, 27 December 2002, Pages 131-141.

12

BHLHE40 is associated with tumor grade in patient-derived breast cancer tissues [67].
Overexpression of BHLHE40 can repress cell proliferation under normal conditions, but
in a hostile environment like hypoxia or low nutrition, BHLHE40 upregulation can
inhibit cell apoptosis and increase tumorigenicity [68]. Under hypoxic stress, BHLHE40,
a direct target of HIF1A [36] is rapidly upregulated and has been shown to increase the
invasiveness of breast cancer cell lines and impart metastatic potential [69]. BHLHE40
has also been shown to increase breast cancer cell proliferation by increasing cyclin E
levels [70]. BHLHE40 mediated suppression of clock (CLOCK/ BMAL1/2) genes
activation, in turn, has been implicated in the modulation of drug toxicity [68]. Therefore,
findings to date show that BHLHE40 plays an important role in the cancer progression
and modulation of tumor response to chemotherapy [71]. However, how BHLHE40
modulates these responses or tumor progression is unclear.
HIF1A stimulates the expression of KDM6B [72], a lysine-specific histone
demethylase that demethylates di- or tri- methylated lysine 27 of histone H3, causing
gene expression. Since it is directly poised to activate genes in answer to up-stream cues,
KDM6B has been investigated for its expression in various tumors. Specifically, KDM6B
is known to increase invasiveness and promote epithelial-mesenchymal transition of
breast cancer cells MDA-MB-231 cells via transcriptional upregulation of SNAI1
expression [73]. EHMT2, another histone modifier modulated by hypoxia [74], is a
histone lysine methyltransferase localized in euchromatin, which acts as a co-repressor
along with partner transcription factors [75]. Increased expression of EHMT2 is
observed in clinical cancer tissues and knockdown of EHMT2 in-vitro induces apoptotic
cell death in various cancer cell lines [76].
Finally, studies have focused intently on chromatin remodelers to elucidate their
roles in hypoxia response modulation, cancer development and disease progression.
Chromatin may assume a state as either euchromatin, containing loosely bound actively
transcribed genes; or as heterochromatin, consisting of compact chromatin associated
with silent genes [77]. Changes in chromatin structure is required for most cellular
processes. Cells, therefore, have strategies in place for relaxing or tightening chromatin
based on cellular cues or requirements. One such mechanism is using ATP-mediated
chromatin remodelers. The well-characterized SWI/SNF (Switch/Sucrose
Nonfermentable Complex) is a chromatin remodeler involved in hypoxia response [58].
SWI/SNF complex is evolutionarily conserved multi-subunit complex, containing the
catalytic subunits with ATPase activity (SMARCA2/BRM or SMARCA4/BRG1) and
other accessory subunits. Presence of SMARCA4 and SMARCA2 at the EPO promoter
under hypoxia demonstrated the importance of this complex in HIF1A mediated
activation of EPO gene[78]. SMARCA4 deletion also led to defects in erythropoiesis and
vascular development in mouse models, which overlap with the known function of
HIF1A targets such as VEGF. Mechanistically, HIF1 and HIF2 recruit SMARCA4
containing SWI/SNF complex to HIF target genes promoter to facilitate ATP dependent
chromatin remodeling and activation of HIF target genes [79]. These studies reflect the
importance of SWI/SNF remodelers in hypoxia response, but the role of the accessory
subunits and their mechanistic link to HIF1A need further investigation. Since research is
now focusing on the importance of chromatin remodelers in hypoxia-mediated
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metastasis, the SWI/SNF complex has received high levels of scrutiny and the functions
of its subunits are being individually studied to identify new avenues to target metastatic
disease progression.
In this study, we analyzed two subunits of the SWI/SNF complex, SMARCE1 and
SMARCA4, for their roles in breast cancer metastasis. Genome-wide transcriptome
studies revealed that BRG1 controls the expression of PI3K/ AKT and BCL2 which are
frequently altered in tumor cells [80]. In breast cancers, SMARCA4 is involved in
progression and metastasis, therefore may serve as a novel biomarker, predictive of
distant metastasis and patient outcomes [81]. SMARCE1, however does not possess any
helicase or ATPase activity but has still been associated with invasive progression of
breast cancer [82]. SMARCE1/BAF57 is an accessory subunit of the SWI/SNF complex
whose function is not completely unraveled.
Orthotopic xenograft models were used to deduce the role of these transcriptional
modulators in MDA-MB-231 cells, a triple negative breast cancer cell-line. A lung
metastatic derivative of MDA-MB-231 (LM) established as previously described [83]
was used to engineer derivatives stably expressing short hairpin RNA (shRNA) against
KDM6B, EHMT2, SMARCA4, SMARCE1, BHLHE40 or empty vector (EV) through
lentiviral transduction and selected in medium containing respective selection drug as
shown in Table 1-1. Mice inoculated with tumor cells were inspected weekly for tumor
appearance by visual observation and palpation. Primary tumor outgrowth was quantified
twice a week using digital calipers. Tumor volume was calculated as: Volume = (width2 x
length)/2. Tumor and lung tissues were extracted 6 weeks after inoculation. The left lung
lobes were imaged using fluorescent microscopy, and metastatic foci in lungs were
quantified using ImageJ software (Figure 1-7).
BHLHE40 and SMARCE1 Knockdown Reduces Lung Metastasis of Breast Cancer
In-Vivo
Primary tumor growth rate was significantly reduced in the BHLHE40
knockdown cells as shown in Figure 1-8A. Spontaneous lung metastatic foci were
measured in percentage metastatic foci occupied in the lung parenchyma following six
weeks of cell inoculation in the mammary fat pad of NSG mice. The mean metastatic foci
of the LM cells and derivatives are as shown in Table 1-2. BHLHE40-KD (knockdown)
and SMARCE1-KD both showed a substantial decrease in lung metastatic foci in lungs
of mice, as shown in Figure 1-8B and C. In addition, BHLHE40 was shown to be
essential for primary tumor growth. This study further investigates the underlying
mechanisms which lead to reduction in the metastatic potential of breast cancer cells by
BHLHE40-KD and SMARCE1-KD.
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Table 1-1.

shRNA construct information.

Gene name
SMARCA4

Catalog#
pBABE BRG1

BHLHE40

TRCN0000232187

KDM6B

MSCV JMJD3

SMARCE1

TRCN0000015779

EHMT2

pLenti6-MK1EHMT2-V5

ControlmCherry

pEZX-AM03

Company
Addgene
Cambridge, MS, USA
Sigma-Aldrich
St.Louis, MO, USA
Addgene
Cambridge, MA, USA
Sigma-Aldrich
St.Louis, MO, USA
Addgene
Cambridge, MA, USA
GeneCopoeia
Rockville, MD, USA

Selection drug
2µg/ml Puromycin
Sigma-Aldrich
2µg/ml Puromycin
Sigma-Aldrich
2µg/ml Puromycin
Sigma-Aldrich
2µg/ml Puromycin
Sigma-Aldrich
30µg/ml Blasticidine
Sigma-Aldrich
2µg/ml Puromycin
Sigma-Aldrich

Plasmids used for knockdown of gene of interest and the selection drug used for
generation of stable knockdown cell line.

E
Figure 1-7.

Orthotropic Xenograft model studies.

5X105 fluorescently labelled cells were injected in the mammary fat pad of 4 weeks old
NSG female mice and 40 days post injections the lungs were harvested and analyzed
under the fluorescence microscope to detect the presence of metastatic foci.
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Figure 1-8.

Fluorescent Lung metastases.

A. Primary tumor growth rate and B. percentage fluorescent lung metastatic foci in mice
injected with LM cells transfected with empty vector (LM EV) and the knockdown
derivatives, calculated using ImageJ software. p<0.05, n=10 C. Fluorescence pictures of
lung metastasis pattern (10X).

Table 1-2.

Mean percentage of metastatic foci in-vivo.

Cell line
LM
LM EHMT2-KD
LM KDM6B-KD
LM SMARCA4-KD
LM SMARCE1-KD
LM BHLHE40-KD

Mean % lung metastatic foci
12.35 ± 5.1
9.08 ± 2.6
8.51 ± 2.3
9.38 ± 2.5
1.02 ± 0.7
7.42 ± 1.9

P value
0.094
0.061
0.115
<0.00001
0.012

Area of mean metastatic foci in mice lung parenchyma inoculated with LM cell lines and
knockdown derivatives. (Highlighted cells show significant reduction in lung metastatic
foci, p<0.05, n=10)
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CHAPTER 2.

ROLE OF SMARCE1 IN METASTATIC BREAST CANCER*
Introduction

Breast cancer is the most frequently diagnosed form of cancer in American
women and is the second leading cause of cancer related deaths, primarily due to the
incurable nature of metastatic breast cancer [84]. Metastasis is the process whereby
cancer cells spread from the site of the primary tumor to distant organs[10]. A stepwise
sequence of events is involved in the metastatic process, during which the tumor cells
encounter many environmental challenges such as loss of attachment to the extracellular
matrix, physical stress during circulation in blood/lymph vessels and immune
surveillance [85, 86]. Only a small fraction of disseminated cells can alter gene
expression patterns to obtain new phenotypic features according to environmental cues,
and ultimately survive and adapt to form metastatic lesions. The mechanics of this
adaptability is an evolving field of study.
Chromatin remodeling plays a key role in tumor progression by altering gene
expression patterns to facilitate rapid adaptation of tumor cells to extracellular stimuli
[87]. Aberrant chromatin remodeling activity is frequently detected in human tumors.
High-throughput genome and/or exome sequencing studies have revealed that the
SWI/SNF (switching-defective and sucrose non-fermenting) chromatin-remodeling
complexes are the most highly mutated chromatin regulatory complexes, with nearly 20%
of human cancers harboring mutations in at least one of the genes encoding SWI/SNF
subunits [88]. Human SWI/SNF complexes consist of either BRG1/SMARCA4 or
BRM/SMARCA2 subunit that possesses helicase and ATPase activity, and several
BRG/BRM associated factors (BAFs) that regulate the DNA binding specificity and
affinity of the complexes [88, 89]. The cancer-associated mutations cause aberrant
activation of the residual SWI/SNF complexes due to distinct subunit configurations,
rather than eliminating the chromatin remodeling activity [90-92]. Although earlier
studies have identified several SWI/SNF subunits (e.g., SMARCB1 and SMARCA4) as
tumor repressors, emerging evidence suggests that SWI/SNF activity is essential for
tumor initiation, maintenance and progression [92, 93]. Therefore, it becomes critically
important to define the role of each SWI/SNF subunit in development and progression of
various types of tumors and adaptability of tumor cells to environmental cues.
Genomic amplification of BAF57/SMARCE1, a core subunit of human SWI/SNF
complexes that play a role in interaction with transcription factors and chromatin, has
been linked to a high-risk of recurrence of estrogen/progesterone receptor-negative breast
tumors [94]. However, the underlying molecular mechanisms remain undefined. In this
study, we demonstrated that SMARCE1 plays a key role in breast cancer metastasis by
protecting breast cancer cells during circulation against anoikis through the HIF1A/PTK2
pathway.
*

Adapted with permission. Fan M, Sethuraman A, et al. “Role of SMARCE1 in
metastatic breast cancer” Breast Cancer Res 2016 Aug 5;18(1):81. [95]
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Methods
Cell culture
All cell lines were purchased from ATCC (Manassas, VA). MDA-MB-231,
HCC38, BT549 and their derivatives were maintained in Minimum Essential Media
(Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS), 200
units/ml penicillin-streptomycin (Cellgro, Manassas, VA, USA) and 0.5 µg/ml
Amphotericin B (Cellgro, Manassas, VA, USA). 184B5 cells were cultured in Mammary
Epithelial Cell Growth Medium (MEGM, Lonza, Switzerland). A lung metastatic
derivative of MDA-MB-231 (LM) was established as previously described [83]. Cells
stably expressing short hairpin RNA (shRNA) against SMARCE1, HIF1A, PTK2 or
empty vector (EV) control were established by lentivirus transduction and selected in
medium containing 2 µg/ml puromycin (Sigma, St Louis, MO, USA). pLKO.1HIF1AshRNA (NM_001530.x-1048s1c1), pLKO.1-SMARCE1shRNA
(TRCN0000015779) and pLKO.1-PTK2shRNA (TRCN0000344599) were obtained from
Open Biosystems/GE Dharmacon (Lafayette, CO, USA) and Sigma-Aldrich (St. Louis,
MO, USA). Cells stably expressing FAK/PTK2 or SMARCE1 were obtained by
lentiviral transduction and selected in medium containing 30 µg/ml blasticidine (Sigma).
pLX304-PTK2 (HsCD00442503) and pLX304-SMARCE1 (HsCD00440078) were
purchased from DNASU Plasmid Repository (Tempe, AZ). Control cells were
established by lentivirus transduction to express selection marker only. Accell
SMARTpool (a mixture of 4 siRNA provided as a single reagent) for human SMARCE1
was obtained from Dharmacon (GE Healthcare Life Sciences, PA) and used to
knockdown SMARCE1 expression by following the manufacture’s protocol. The Accell
Human Control siRNA (non-targeting) was used as control oligonucleotides.
Orthotopic xenograft model and experimental lung metastasis model (tail-vein
injection)
All animal studies adhered to protocols approved by the Institutional Animal Care
and Use Committee of University of Tennessee Health Science Center. For orthotopic
xenograft model in NSG mice (NOD.Cg Prkdcscid Il2rgtm1Wjl/SzJ, The Jackson
Laboratory), cells (7.5x105 cells in 10 µl Phosphate-buffered saline) were surgically
inoculated into the right inguinal mammary gland fat pads of 4-week old female mice as
previously described [96]. Mice were inspected weekly for tumor appearance by visual
observation and palpation. Primary tumor outgrowth was monitored twice a week using
digital calipers. Tumor volume was calculated as: Volume = (width2 x length)/2. Tumor
and lung tissues were extracted 6 weeks after inoculation. The left lung lobes were
imaged under the fluorescent microscope, fixed with 4% paraformaldehyde, followed by
tissue section (10µm) and hematoxylin and eosin staining. Metastatic foci in lungs were
quantified using ImageJ software. For experimental lung metastasis model, cells were
inoculated into to 4-week old NSG mice by tail vein injection. Whole blood was
collected by cardiac puncture at various time and subjected to ficoll-paque separation as
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per manufacturer’s protocol immediately after collection (Ficoll-Paque PLUS, GE
Healthcare Life Sciences, Piscataway, NJ) to isolate circulating tumor cells. Fluorescent
circulating tumor cells were counted under fluorescent microscope using a 10X objective.
Quantitation of mRNA using qPCR
Total RNA was prepared with Trizol (Life technologies, Grand Island, NY),
chloroform and isopropanol. mRNA concentration and quality was analyzed on the
NanoDrop (ThermoScientific, USA). cDNAs for mRNA were synthesized by using
iScript cDNA Synthesis Kits (BioRad, Hercules, CA). qPCR was performed on the
CFX96™ Real-Time PCR Detection System using SYBR Green Supermix (BioRad).
Expression data of mRNA were normalized by the 2-ΔΔCT method to RPL13A, and
presented as mean ± SE (n=3). qPCR primers were obtained from PrimerBank [97].
Migration and invasion assays
Cells (20,000 cells/0.5 ml/well) were plated onto control membrane inserts with
8-micron pores (migration assay) or Matrigel-coated membrane transwell inserts
(invasive assay) (BD Biosciences, Bedford, MA), which were placed in 24-well
chambers filled with 0.6 ml growth medium. Twenty-four hours after plating, cells that
remained on the upper surface of the membrane were removed by cotton tipped swabs,
and cells that migrated/invaded to the lower surface of the membrane were viewed under
the fluorescent microscope. The fluorescent cell pictures were analyzed on ImageJ and
percent migration was expressed as % migration = (mean number of cells migrating
through Matrigel insert membrane x 100/ mean seeding control) and percent invasion was
expressed as: % invasion = (mean number of cells invading through Matrigel insert
membrane x 100) / mean number of cells migrating through control insert membrane.
Suspension culture and inhibitor assays
To mimic loss of attachment, 105 cells/well were seeded in 6-well culture dishes
coated with polyHEMA (Sigma, St Louis, MO, USA) to prevent cell adherence for
various periods of time. Cells were inoculated with 3ml of growth medium initially with
no further manipulation throughout the course of the experiment. Cell suspensions were
placed into standard culture dishes 16 hours prior to end-point viable cell counting.
To identify the signaling pathways that promote survival of detached cells, a
panel of chemical inhibitors were added in culture medium to cells plated in polyHEMA
coated dishes: PTK2/FAK inhibitor - 0.5 µM PF562271 (Selleckchem, Houston, TX),
MAPK1/2 inhibitor – 10 µM U0126 (LC Laboratories, Woburn, MA) or 10 µM
PD98059 (Santa Cruz Biotechnology, Dallas, TX), AKT inhibitor – 30 µM ZSTK474
(LC Laboratories), TGFBRI/II inhibitor – 10 µM LY2109761 (Selleckchem), SRC
inhibitor – 3 µM Dasnitib (LC Laoratories) or Notch inhibitor – 5 µM DAPT
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(Selleckchem). Following a 7-day incubation, cells were plated back on the standard
culture dishes and quantified 16 hours later.
Protein extraction and immunoblotting
Protein extraction from whole cells was prepared with radioimmunoprecipitation
buffer, cytosolic and nuclear fractions was prepared by NE-PER Nuclear and
Cytoplasmic Extraction Reagents (ThermoScientific). Protein lysates were resolved on 810% SDS-PAGE and transferred to polyvinylidene fluoride membrane and
immunoblotted with the following antibodies: anti-PTK2/FAK, FAK-Tyr576P/Tyr577P,
MAPK1/2-Thr202P/Tyr204P, MAPK1/2, AKT-Tyr416P, AKT and BCL2L11 from Cell
Signaling Technologies (Boston, MA); anti-HIF1A from Novus Biologicals (Littleton,
CO); anti-SMARCE1 and SMARCA4 from Bethyl Laboratories (Montgomery, TX);
anti-GAPDH from Millipore (Merck, Darmstadt, Germany) and anti-TBP from Abcam
(Cambridge, MA). Luminescence detection of these membranes were performed as
previously discussed [83].
Chromatin immunoprecipitation
Cells (2x107) were cross-linked with 1% formaldehyde (Pierce™ 16%
Formaldehyde (w/v), Methanol-free, Life Technologies) for 15 minutes. The nuclear
fraction was prepared using the NE-PER™ Nuclear and Cytoplasmic Extraction
Reagents (Life Technologies), chromatin was sheared by sonication to obtain ~500 bp
fragments and the soluble fraction was collected after centrifuge (12,000rpm, 15 min).
The soluble nuclear fractions were pre-cleaned with control IgG and MagnaBind Goat
anti-Rabbit IgG (Life Technologies) and used for immunoprecipitation with antibodies
against HIF1A, SMARCE1 or SMARCA4. Immunocomplexes were isolated with
MagnaBind Goat anti-Rabbit IgG, de-crosslinked, and subjected to DNA preparation
using the MiniElute PCR Purification Kit (QIAGEN, Germantown, MD). qPCR was
performed to detect the presence of PTK2 promoter region by using primers (Forward:
5’-CTCTTCCTCCTCCTGCCTCT-3’; reverse 5’-GTTCGGGGAAGACAGAAA GG3’). To detect protein-protein interaction, the immunocomplexes were dissolved in
Laemmli Sample Buffer (Bio-Rad) and subjected to immunoblotting assay.
Caspase assay
5x105 cells were plated in polyHEMA coated dishes and Caspase-3 levels were
measured at indicated time points using the Caspase-Glo® 3/7 assay kit (Promega). The
cells were lysed with lysis buffer provided with the kit and substrate and lysis mix was
incubated for 30 minutes with rotation and quantifies via luminometer. Caspase activity
was calculated as per manufacturer protocol and, normalized to cell numbers.
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Nucleosome scanning assay (NUSA)
106 cells were placed under suspension culture in polyHEMA coated dishes for 0,
0.5, 1 and 2 hours, respectively. Nuclei were isolated, treated with Atlantis Double-strand
specific DNased (dsDNase) and subjected to DNA purification according to the EZ
Nucleosomal DNA prep kit (Zymo Research). qPCR was performed to determine
nucleosome positioning on the PTK2 promoter. Overlapping primers were designed from
-150 to +1589 relative to start site of PTK2 promoter to generate amplicons of ~150 bp,
the size of DNA covered by one nucleosome. DNA amount was calculated according to a
standard curve (qPCR CTs vs. various concentrations of template) generated for each
primer and normalized to qPCR CTs of DNA purified from equal number of nuclei
untreated with dsDNAase.
Statistical analysis
ANOVA and post-hoc least significant difference analysis or t-tests were
performed using GraphPad Prism 5 software. P values < 0.05 (*) were considered
statistically significant. Data from two or three independent experiments with replicates
are presented as means ± sd.
Results
SMARCE1 knockdown reduces lung metastasis of breast cancer in vivo
To define the role of SMARCE1 in breast cancer metastasis, we examined the
effect of SMARCE1 knockdown on spontaneous lung metastasis using an orthotopic
xenograft mouse model derived from a lung metastatic variant of MDA-MB-231 cells,
previously described and designated as LM [83]. SMARCE1 knockdown showed no
significant effect on the latency and growth rate of primary xenografts in mammary gland
fat pads (Figure 2-1A and B, LM-SMARCE1-KD vs. LM-EV), but substantially reduced
both the number and size of metastatic foci in lungs (Figure 2-1C, LM-SMARCE1-KD
vs. LM-EV). According to the images of lung tissue sections, metastatic foci occupied
12.30 ± 3.87 % of the lung parenchyma in mice 6-wk after inoculation with LM-EV cells,
which was reduced to 1.02 ± 0.76 % in mice inoculated with LM-SMARCE1-KD cells
(p=0.0002) (Figure 2-1C, bar graph). By examining the number of tumor cells in blood,
we found that SMARCE1 knockdown significantly reduced the number of circulating
tumor cells (p=0.0011) (Figure 2-1D) in mice inoculated with LM cells. Together, these
results suggest that SMARCE1 activity is dispensable for primary tumor outgrowth, but
essential for distant metastasis of MDA-MB-231 cells.
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Figure 2-1.
vivo.

SMARCE1 knockdown reduces lung metastasis of breast cancer in

A. Expression levels of SMARCE1 mRNA and protein in LM-EV and LM-SMARCE1KD cells B. Effect of SMARCE1 knockdown on the growth of xenografts in the fourth
inguinal mammary fat pads of female NSG mice, n=6 C. Spontaneous lung metastasis
from orthotopic sites. Metastatic foci of tumor cells expressing red fluorescent protein on
the dorsal surface of the left lung lobe were imaged 38 days after tumor cell inoculation
(left panel). The presence of tumor cells in the lungs was visualized by hematoxylin and
eosin (H&E) staining of formalin-fixed lung sections (10 μM) and quantified by ImageJ
software (right panel) n=6. D. Number of circulating tumor cells in blood. Fluorescent
tumor cells in mouse blood were isolated and counted 38 days after tumor cell
inoculation. (n=5)
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SMARCE1 knockdown reduces lung colonization of tumor cells inoculated through
tail vein
Metastasis is a multi-step process, involving local invasion, circulation,
extravasation, colonization and outgrowth of metastatic foci [98]. To identify the steps of
this metastatic cascade that requires SMARCE1 activity, we examined the effect of
SMARCE1 knockdown on the ability of tumor cells to survive circulation and colonize
lungs by using an experimental metastasis model. LM-EV and LM-SMARCE1-KD cells
(5x105) were injected into the left lateral tail-vein of 5-wk old female NSG mice. Tumor
cells in the bloodstream and lung tissues were examined at various time after injection
(Figure 2-2A). As expected, the number of circulating tumor cells in blood decreased
over time. Interestingly, at any given time point, the number of LM-EV cells in
bloodstream was significantly higher than that of the LM-SMARCE1-KD cells (Figure
2-2A). At 72 hours post tail vein injection, we analyzed whole lung lobes under
fluorescent microscope and observed red fluorescent tumor cells in lungs of mice
inoculated with LM-EV cells but not in mice with LM-SMARCE1-KD cells (Figure
2-2B). Four weeks post injection, a lower number of tumor foci were observed in lungs
of mice inoculated with LM-SMARCE1-KD cells compared to mice with LM-EV cells
(Figure 2-2C). Together, these results suggest that SMARCE1 knockdown diminishes
the ability of tumor cells to survive circulation, thus leading to an overall reduction of
lung metastatic foci in mice injected with SMARCE1 knockdown cells.
SMARCE1 knockdown sensitizes tumor cells to anoikis
Our in vivo experiment results implicate SMARCE1 as an essential contributor in
distant metastasis of breast cancer cells by promoting the survival of circulating tumor
cells. However, it is unclear whether SMARCE1 plays a role in early metastatic events
such as cell migration and invasion. To examine the effect of SMARCE1 knockdown on
the migratory and invasive potential of tumor cells, we performed Boyden Chamber
Transwell assays. Cells were plated in uncoated Boyden chambers to measure their
migratory potential, and in matrigel coated chamber to determine their invasiveness. As
showed in Figure 2-3A, SMARCE1 knockdown in LM cells significantly increased cell
migratory potential, but showed no significant effect on cell invasiveness. This
observation suggests that SMARCE1 activity is dispensable for cell migration. Next, we
examined the effect of SMARCE1 knockdown on cell sensitivity to anoikis by
monitoring cell viability after cultured in dishes coated with PolyHEMA to prevent
attachment. As showed in Figure 2-3B, SMARCE1 knockdown in LM cells
substantially reduced the number of viable cells cultured in suspension. This result is
consistent with our results from in vivo experiments and confirms that SMARCE1 plays a
key role in protecting LM cells against anoikis, a form of cell death induced by
detachment.
To determine whether SMARCE1-mediated anoikis resistance ability can be
extended to other breast cancer cell lines, we examine the effect of SMARCE1
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Figure 2-2. SMARCE1 knockdown reduces lung colonization of tumor cells
inoculated through tail veins.
A. Number of circulating tumor cells in blood collected at various time points after tail
vein injection in NSG mice. B. Fluorescent tumor cells in lungs of NSG mice 72h after
tail vein injection. Representative images of five lungs for each group were shown. C.
Fluorescent tumor foci in the left lung lobes of NSG mice 4-wk after tail vein injection of
tumor cells. The area of tumor foci on the dorsal surface of the left lung lobe was
quantified by ImageJ.

24

Figure 2-3.
anoikis.

SMARCE1 knockdown promotes cell migration, but sensitize cells to

A. Effect of SMARCE1 knockdown in LM cells on cell migration and invasion. Boyden
chambers, uncoated or coated with matrigel were used to measure cell migratory and
invasive potential, respectively. Percent migration/invasion was calculated as per
manufacturer’s protocol B. Effect of SMARCE1 knockdown in LM cells on viability of
cells cultured in dishes coated with PolyHEMA to prevent adhesion. C. Effect of
SMARCE1 knockdown in HCC38 cells. D. SMARCE1 overexpression in BT549 cells.
E. Blocking SMARCE1 expression by siRNA enhanced detachment-induced caspase
activation in LM and HCC38 cells. Accell SMARTpool of SMARCE1-siRNA (1 µM)
were delivered into cells 48 h prior to detachment. Caspase activities were determined at
indicated time point after cell detachment by using the Caspase-Glo 3/7 assay kit.
*p<0.05, n=6, Student T-test.
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knockdown in HCC38 (Figure 2-3C), a triple-negative breast cancer cell line. We found
that SMARCE1 knockdown resulted in significant reduction of the viability of cells in
suspension culture. In addition, we examined the effect of SMARCE1 overexpression in
BT549, a triple-negative breast cancer cell line that lacks SMARCE1 expression due to a
biallelic inactivating mutation that causes a frameshift [99]. As expected, no SMARCE1
mRNA or protein was detected in BT549 cells (Figure 2-3D). Enforced SMARCE1
overexpression in BT549 substantially increased the viability of cells in suspension
culture. To validate the observations with SMARCE1-shRNA, we examined the effect of
SMARCE1 siRNA (Accell SMARTpool, GE Dharmacon) or control oligonucleotides on
anoikis in LM and HCC38 cell lines. As showed in Figure 2-3E, SMARCE1 siRNA
(SMARCE1-i) treatment resulted in decreased expression of SMARCE1 protein and
enhanced activation of caspase 3/7 in cells under suspension culture. These results
demonstrate that SMARCE1 plays role in anoikis resistance of breast cancer cells.
SMARCE1-mediated anoikis resistance requires activation of PTK2, MAPK and
AKT pathways
To gain insights into the molecular mechanisms underlying SMARCE1-mediated
anoikis resistance, we sought to identify signaling pathways regulated by SMARCE1 in
detached cells by using chemical inhibitors of several signaling pathways that have been
linked to anoikis resistance of cancer cells [100, 101]. As showed in Figure 2-4A,
inhibitors of focal adhesion kinase (PTK2/FAK), MAPK and AKT significantly reduced
the viability of LM-EV cells in suspension culture. In contrast, these inhibitors showed
no significant effect on LM-SMARCE1-KD cells. The same experiments were performed
with BT549-EV and BT549-SMARCE1 cells and the result showed that SMARCE1mediated increase of cell viability was effectively abolished by inhibitors of PTK2,
MAPK and AKT (Figure 2-4B). In agreement with the observed effects of chemical
inhibitors on cell viability, immunoblotting analysis showed that LM-EV cells in
suspension culture had higher levels of PTK2 protein, MAPK phosphorylation and AKT
phosphorylation compared to LM-SMARCE1-KD cells (Figure 2-5A). In addition,
elevated expression of the pro-apoptotic protein BIM/BCL2L11, a marker of onset of
anoikis in breast cancer cells, was detected in suspension cultures of LM-SMARCE1-KD
cells, but not in LM-EV cells (Figure 2-5A). Consistently, higher levels of PTK2 protein
and AKT phosphorylation, concomitant with lower levels of BIM protein, were observed
in HCC38-EV cells as compared to HCC38-SMARCE1-KD cells in suspension culture
(Figure 2-5B). However, MAPK phosphorylation was not affected by cell detachment or
SMARCE1 knockdown in the HCC38-EV cells. In addition, elevated expression levels of
PTK2 protein, MAPK phosphorylation and AKT phosphorylation, but diminished levels
of BIM, were detected in BT549-SMARCE1 cells in comparison to control BT549-EV
cells under suspension culture (Figure 2-5C). Together, these results suggest that
activation of PTK2, MAPK and AKT survival pathways are critical for breast cancer
cells to survive anoikis, and SMARCE1 activity is required for the activation of these
pro-survival pathways in detached cells.
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Figure 2-4. SMARCE1-mediated anoikis resistance requires activation of PTK2,
MAPK and AKT pathways.
A. Viability of LM-EV and LM-SMARCE1-KD cells cultured in PolyHEMA-coated
dishes in the absence or presence of indicated inhibitors. B. Viability of BT549-EV and
BT549-SMARCE1 cells cultured in PolyHEMA-coated dishes in the absence or presence
of indicated inhibitors. For all experiments, viable cells were counted after 7 days in
suspension culture. Concentration of inhibitors: 0.5µM PF562271, 10µM U0126, 10µM
PD98059, 30µM ZSTK474, 3µM Dasnitib, 5µM DAPT and 10µM LY2109761. *p<0.05,
n=3, Student T-test.
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Figure 2-5. SMARCE1-dependent activation of PTK2, MAPK and AKT
pathways by cell detachment.
A. Effect of SMARCE1 knockdown in LM cells on detachment-induced activation of
pro-survival (FAK/PTK2, MAPK and AKT) and pro-apoptotic (BIM) signaling
pathways. B. Effect of SMARCE1 knockdown in HCC38 cells. C. Effect of SMARCE1
overexpression in BT549 cells. The levels of protein expression and phosphorylation
were determined by immunoblotting assays. GAPDH was included as a loading control.

28

SMARCE1 collaborates with HIF1A to activate PTK2 transcription in detached
cells
Aberrant activation of PTK2, a non-receptor tyrosine kinase involved in focal
adhesion, has been recognized as a key mediator of anoikis resistance in variety of tumor
cells [100, 102]. For example, PTK2 activation has been detected in circulating tumor
cells isolated from 90% of patients with metastatic breast tumors, implicating a role of
PTK2 in breast cancer metastasis [103]. Therefore, we sought to examine whether
SMARCE1 regulates PTK2 expression in detached cells. Based on immunoblotting and
qPCR analysis, we found that cell detachment induced PTK2 expression at both the
protein level (Figure 2-5) and mRNA level (Figure 2-6A) in a SMARCE1-dependent
manner in LM, HCC38 and BT549 cells. This observation suggests that SMARCE1 is
required for PTK2 gene activation on a transcriptional level in detached cells.
By inspecting the transcription factor binding consensus sequences in the
proximal promoter region of PTK2 gene (Figure 2-6B), we found a potential
HIF1A/ARTN binding site located in the binding region of SWI/SNF subunits
(SMARCA4 and SMARCB1) identified by ENCODE TFBS ChIP-seq analysis [104].
Normoxic HIF1A activation has been linked to anoikis resistance in breast cancer cells
[103, 105]. In addition, SWI/SNF complexes were reported to play a role in modulating
HIF1A-mediated transcription activation in cells under hypoxia [79, 106]. Therefore, we
speculated that SMARCE1 regulates PTK2 gene transcription through HIF1A in detached
cells. Using CHIP-qPCR assays, we showed that that cell detachment induced
recruitment of SMARCE1, HIF1A and BRG1/SMARCA4 to the PTK2 promoter region
(-874 to -575 bp) in LM-EV cells, which was abolished by SMARCE1 knockdown
(Figure 2-6B). In addition, using reciprocal immunoprecipitation assays, we detected
HIF1A and SMARCE1 proteins in the immunoprecipitated SMARCE1 and HIF1A
complexes, respectively (Figure 2-6C). These results suggest that SMARCE1 activity is
required for HIF1A-mediated PTK2 transcription activation in detached cells.
Since the SWI/SNF complex is involved in nucleosomal remodeling we sought to
examine changes in the nucleosomal positioning on the PTK2 promoter. Nucleosome
scanning assay (NUSA) was performed to examine the consequence of SMARCE1 and
HIF1A binding to the PTK2 promoter in detached cells. We found that cell detachment
induced nucleosomal disassembly on the PTK2 promoter region bound by HIF1A and
SMARCE1, indicated by increased sensitivity of PTK2 promoter to dsDNase digestion,
which resulted in decreased amount of DNA detected by qPCR (Figure 2-7). However,
cell detachment did not increase dsDNase sensitivity of PTK2 promoter in LMSMARCE1-KD cells (Figure 2-7B, right panel). These observations support the role of
SMARCE1 in chromatin remodeling of PTK2 promoter and HIF1A-mediated PTK2
transcriptional activation in detached cells.
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Figure 2-6. SMARCE1 collaborates with HIF1A to activate PTK2 transcription
in detached cells.
A. Detachment-induced PTK2 mRNA expression is abolished by SMARCE1 knockdown
in LM and HCC38 cells, whereas enhanced by SMARCE1 overexpression in BT549
cells. B. Detachment-induced recruitment of HIF1A and SMARCA4 to the promoter
region of PTK2 is diminished by SMARCE1 knockdown in LM cells. Chromatin binding
of HIF1A, SMARCE1 and SMARCA4 was measured by ChIP-qPCR assay. Average
fold enrichment of PTK2 promoter DNA by indicated antibodies (vs. control IgG) from
three independent experiments are presented. C. Detachment induces interaction between
SMARCE1 and HIF1A in LM-EV and LM-SMARCE1-KD cells. The protein interaction
was examined by Immunoprecipitation/Immunoblotting assays. *p<0.05, Student T-test.
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Figure 2-7. SMARCE1 orchestrates chromatin remodeling of PTK2 promoter in
detached cells.
A. Overlapping primer designed for the nucleosome scanning assay and their amplicon
sizes. The location of each primer set is given relative to the transcription start site (TSS).
B. Significant nucleosomal displacement is observed on PTK2 promoter (from -802 to 492 bp, encompassing HIF1A binding site) in LM-EV cells after 0.5, 1 and 2 hours under
suspension culture (vs. adherent cells), but not in LM-SMARCE1-KD cells. Results from
three independent experiments were presented as means ± SE.
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HIF1A activates PTK2 transcription and downstream activation of survival
pathways in detached cells
To confirm that HIF1A-mediated PTK2 transcription is critical for breast cancer
cell to survive anoikis, we examined the effect of HIF1A knockdown on cell sensitivity
to anoikis and detachment-induced activation of PTK2, MAPK and AKT. HIF1A
knockdown in MDA-MB-231 cells effectively dampened detachment-induced HIF1A
protein accumulation and PTK2 mRNA expression (Figure 2-8A and B), and reduced the
number of viable cells in suspension culture (Figure 2-8C). Immunoblot analysis showed
levels of PTK2, phosphorylated-PTK2 (pTyr576/577), phosphorylated-MAPK
(pThr202/Tyr204) and phosphorylated-AKT (pTyr416) were significantly lower in
HIF1A-KD cells than that in control MDA-MB-231-EV cells under suspension culture
(Figure 2-8D). Conversely, the pro-anoikis protein BIM was induced only in detached
HIF1A-KD cells. To confirm that MAPK and AKT phosphorylation are downstream
events of PTK2 activation in detached cells, we examined the effect of PTK2 inhibition
by PF562271 on activation of these pathways. As showed in Figure 2-8E, pre-treatment
with PF562271 effectively abolished detachment-induced phosphorylation of PTK2,
MAPK and AKT. Taken together, these results suggest that HIF1A-mediated PTK2
transcription activation plays a key role in protecting cells against anoikis by sustaining
the activation of survival signaling pathways (MAPK and AKT), as well as suppressing
pro-apoptotic signaling (BIM).
To corroborate the role of PTK2 in SMARCE1-mediated anoikis resistance, we
examined the effects of PTK2 overexpression and PTK2 knockdown on anoikis
sensitivities of LM-SMARCE1-KD and BT549-SMARCE1 cells, respectively. We found
that PTK2 overexpression effectively rescued LM-SMARCE1-KD cells from anoikis,
which is indicated by increased number of viable cells and reduced caspase activation
(Figure 2-9A, B, C, and D). Conversely, PTK2 knockdown abolished SMARCE1mediated protection of BT549 cells against anoikis (Figure 2-9E and F).
SMARCE1 knockdown sensitizes non-tumorigenic mammary epithelial cells to
anoikis
To examine whether the SMARCE1-dependent anoikis resistance occur at early
stage of tumorigenesis, we examined the effect of SMARCE1 knockdown on anoikis
sensitivity of 184B5, a mammary epithelial cell line immortalized by benzo(a)pyrene
exposure [107]. Previous studies showed that 184B5 was not tumorigenic in
immunosuppressed mice, but 184B5 does not form colonies in semisolid medium [107].
Therefore, 184B5 represents cells at early stage of tumorigenesis. We found that
SMARCE1 inhibition in 184B5 cells, by either stable knockdown through shRNA
expression (Figure 2-10A) or transient siRNA delivery (Figure 2-10B), blocked
detachment-induced PTK2 upregulation (Figure 2-10C) and sensitized cells to anoikis,
indicated by reduced cell numbers and increased caspase activation (Figure 2-10A and
B, respectively). These observations suggest that SMARCE1/PTK2-mediated anoikis
resistance is an early event of tumorigenesis.
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Figure 2-8. HIFIA activates PTK2 transcription and downstream survival
pathways in detached cells.
A. Detachment induced HIF1A protein accumulation is eliminated by HIF1A knockdown
in MDA-MB-231 cells. B. HIF1A knockdown abolishes detachment induced PTK2
mRNA expression in MDA-MB-231 cells. C. HIF1A knockdown sensitizes MDA-MB231 cells to anoikis. Viable cells in suspension culture for 10 days were counted. D.
Effect of HIF1A knockdown in MDA-MB-231 cells on detachment-induced activation of
pro-survival (PTK2, MAPK and AKT) and pro-apoptotic (BIM) signaling pathways. E.
Effect of PTK2 inhibition in MDA-MB-231 cells on detachment-induced activation of
pro-survival and pro-apoptotic signaling pathways. The mRNA levels were measured by
qPCR. The levels of protein expression and phosphorylation were determined by
immunoblotting assays with GAPDH included as a loading control. *p<0.05, Student Ttest.
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Figure 2-9. PTK2 activation is essential for SMARCE1-mediated anoikis
resistance in breast cancer cells.
A. Expression levels of PTK2 mRNA in LM derivatives. B. PTK2 protein expression and
phosphorylation in LM derivatives cultured in PolyHEMA-coated dishes. Intensities of
immunoblotting signals were quantified by ImageJ and the average of normalized
intensities (vs. GAPDH) from three independent experiments were presented. C. Effect
on PTK2 overexpression on viability of LM derivatives cultured in PolyHEMA-coated
dishes. D. Effect on PTK2 overexpression on caspase activation in LM derivatives
cultured in PolyHEMA-coated dishes. Caspase activity was normalized to cell numbers
and results from three independent experiments were presented as means ± SE. E.
Expression levels of PTK2 mRNA in BT549 derivative. F. Effect of PTK2 knockdown
on viability of BT549 derivative cultured in PolyHEMA-coated dishes. *p<0.05, Student
T-test, LM= lung metastatic derivative of MDA-MB-231 cells.
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Figure 2-10. Blocking SMARCE1 expression sensitizes non-tumorigenic mammary
epithelial cells to anoikis.
A. Effect of SMARCE1 knockdown by stable shRNA expression on viability of 184B5
cells cultured in PolyHEMA-coated dishes. B. Effect of stable shRNA expression
(SMARCE1-KD) and SMARCE1-siRNA delivery (SMARCE1-i) on caspase activation
in 184B5 cells cultured in PolyHEMA-coated dishes. Caspase activity was measured by
using the Caspase-Glo 3/7 assay kit and normalized to cell numbers. The results from
three independent experiments were presented as means ± SE. C. Detachment-induced
PTK2 mRNA expression is abolished by SMARCE1-KD or SMARCE1-i in 184B5 cells.
mRNA levels were measured by qPCR. *p<0.05, n=3, Student T-test.
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Higher SMARCE1 and PTK2 expression is associated with poor prognosis of
patients with basal-like or luminal B subtype of breast tumors
Having established a role of SMARCE1 in regulating metastatic potential of
breast cancer cells through the HIF1A/PTK2 pathway, we sought to elucidate the clinical
relevance of this finding by examining the relationship between the SMARCE1 and
PTK2 expression and the clinical outcomes of breast cancer patients. Analyzing
expression data of 3554 breast tumor samples collected by an online Kaplan-Meier
survival analysis tool [108], we found that higher expression of SMARCE1 or PTK2 is
associated with shorter interval of relapse free survival (RFS) of breast cancer patients
(Figure 2-11A). However, this RFS was not correlated when tumor samples were
grouped according to ESR1 expression or intrinsic PAM50 subtype markers. Next, we
examined the relationship between the expression of SMARCE1 and PTK2 in breast
tumors in The Cancer Genome Atlas (TCGA) database [109]. No significant correlation
between SMARCE1 and PTK2 expression was detected when data from all breast tumors
(n=825) were included in the analysis. However, after tumors were stratified according to
the intrinsic PAM50 subtype markers, a positive correlation between SMARCE1 and
PTK2 expression was detected in the luminal B and basal-like cohorts (Figure 2-11B),
but not in the human epidermal growth factor receptor 2, ERBB2-enriched or Luminal A
cohorts. Together, these observations suggest that higher expression of SMARCE1 and
PTK2 increases risk of tumor relapse, and SMARCE1 likely plays a key role in
regulating PTK2 expression in luminal B and basal-like tumors.
Genomic alterations contribute to deregulation of SWI/SNF complexes in breast
cancer
Despite the prevalent notion that SWI/SNF complexes are tumor suppressors
[110], emerging evidence suggests that genetic alterations of subunit genes can produce
aberrant SWI/SNF complexes with oncogenic function [111]. These findings prompted
us to examine the nature and frequency of genetic alterations in SMARCE1 and other
SWI/SNF subunits specifically in breast cancer by using the TCGA database. The result
revealed that approximately 30% breast tumors harbor genetic alterations in one or more
of the genes encoding SWI/SNF subunits (Figure 2-11C). Interestingly, gene
amplification is the most frequent genetic event for multiple SWI/SNF subunits in breast
cancer, rather than inactive mutations that were reported in other tumors [88]. SMARCE1
is the second most frequently amplified gene among all the SWI/SNF subunits. This
finding implicates an oncogenic role of SWI/SNF complexes in human breast cancer. If a
SWI/SNF subunit plays a critical role in promoting progression of breast cancer, we
speculate a positive correlation between its expression and poor prognosis of breast
cancer patients. Therefore, we examined the relationship between the expression of each
SWI/SNF subunit and interval of RFS of breast cancer patients using the online KaplanMeier survival analysis tool [108]. This analysis revealed higher expression of 9 (out of
31) SWI/SNF subunits (i.e., BCL7C, BRD7, ACTL6A, SMARCE1, SMARCA5,
SMARCAL1, SMARCA4, SS18 and SMARCC1) is associated with shorter interval of
RFS of breast patients (LogRank p<0.05, n=3550). Overall the
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Figure 2-11. Higher SMARCE1 and PTK2 expression is associated with poor
prognosis of breast cancer patients.
A. Kaplan-Meier analysis of recurrence-free survival (RFS) of breast cancer patients
based on SMARCE1 and PTK2 expression using dataset of 3554 breast tumor samples
(http://kmplot.com/analysis/). To construct Kaplan-Meier curves all percentiles between
the lower and upper quartiles were computed and the best performing threshold was used
as cutoff to divide the patient cohort. The LogRank test P value was calculated by using
RFS up to 15 years as endpoint. B. Correlated expression of SMARCE1 and PTK2 in
basal-like and luminal B subtypes of breast cancer according to the TCGA database.
Tumors with PTK2 amplification were excluded from the correlation analysis. C.
Frequency of genetic alterations of SWI/SNF complex subunits in breast tumors
according to the TCGA database.
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results from genetic and expression data analysis suggest that deregulation of SWI/SNF
activity by altering expression of core subunits likely plays a key role in promoting breast
cancer progression.
Discussion
Loss of adhesion to extracellular matrix (ECM) triggers a specific form of
apoptosis termed anoikis in normal epithelial cells [112], which plays a fundamental role
in morphogenesis of the mammary gland ductal system [113]. Circumvention of anoikis
contributes to breast tumor development and is a prerequisite for metastases by allowing
cells to survive loss or alterations of ECM [85, 100]. In mammary epithelial cells, the
dynamic and magnitude of activation of pro-apoptotic genes (e.g., BIM and BMF) or prosurvival proteins (e.g., PTK2) were shown to play a critical role in determining the fates
of detached cells, anoikis or survival [38, 85, 100, 114]. PTK2 is one of the most
important signaling proteins recruited into focal adhesions upon cell-ECM contact, where
PTK2 is rapidly auto-phosphorylated to enable the recruitment of other scaffold and
signaling molecules to activate the downstream cell survival signaling pathways (e.g.,
PI3K/Akt and MAPK/ERK pathways) [102, 114, 115]. Emerging evidence suggests that
PTK2 plays a key role in protecting tumor cells against anoikis by sustaining survival
signaling [100, 102]. However, how PTK2 is activated in detached cells has not been
definitively resolved. Our studies revealed a key role of SMARCE1 in promoting
survival of detached cells by facilitating rapid PTK2 transcription activation through
HIF1A, the master regulator of hypoxia responsive genes. Multiple kinases were reported
to activate PTK2 through phosphorylation at Tyr576/577 in detached cells, including
SRC family kinases and PTK6 [100, 116]. We found that SRC inhibition by Dastinib, a
SRC family tyrosine kinase inhibitor, had no effect on viability of LM and BT549 cells
under suspension. This observation suggests that PTK2 phosphorylation in detached
breast cancer cells is likely sustained by an SRC-independent mechanism.
HIF1A activation under normal oxygen tension has been linked to anoikis
resistance of breast cancer cells driven by the ERBB2 oncogene [105], and circulating
breast tumor cells from patients with metastatic breast cancer [103]. SWI/SNF complexes
were shown to regulate transcription activation of a subset of HIF1A target genes under
hypoxia [106]. However, it is unclear whether the SWI/SNF complex is required for
HIF1A transcription activity in detached cells under normal oxygen tension. Our study
provides evidence suggesting an essential role of SMARCE1-based chromatin
remodeling activity in breast cancer metastasis by facilitating HIF1A mediated PTK2
transcription activation in detached cells under normoxia. Further study is warranted to
evaluate the anti-metastastic potential of approaches targeting SMARCE1-HIF1A
interaction.
According Project Achilles, the database which performed genome-wide pooled
shRNA screens across hundreds of cancer cell lines to identify genes essential for tumor
cell proliferation, SMARCE1 knockdown showed limited effect on proliferation of breast
cancer cells [117]. Consistently, we found that SMARCE1 knockdown had no

38

significantly effect on proliferation of breast cancer cell lines -MDA-MB-231 and
HCC38; in vitro and growth of orthotopic xenografts derived from MDA-MB-231 cells.
However, SMARE1 knockdown did significantly enhanced anoikis sensitivity of breast
cancer cells. These findings suggest that SMARCE1 is dispensable for proliferation of
breast cancer cells under normal growth condition, but required for cells to survive
anoikis. Whether SMARCE1 plays a role in protecting cells against stress-induced cell
death in general requires further investigation.
In contrast to colorectal cancer, melanoma or lung cancers which frequently
harbor inactive mutations of SWI/SNF subunits, breast tumors have a relatively low
frequency of inactive mutations [88, 92, 93]. By inspecting the TCGA database we found
that ~30% breast tumors harbor genetic alterations (e.g., gene amplification, deletion and
mutation) in one or more of the SWI/SNF subunits, with gene amplification being the
most frequent event. This finding implicates an oncogenic role of SWI/SNF complexes in
breast cancer. Consistently, we found that higher expression of several SWI/SNF
subunits was associated with shorter interval of RFS of breast cancer patients. Our
findings are likely relevant to basal-like and luminal B breast tumors subtypes, due to a
positively correlated expression profile between SMARCE1 and PTK2. In conclusion,
this study establishes a novel role of SMARCE1 in regulating metastatic potential of
breast cancer cells by promoting survival of detached cells through the HIF1A/PTK2
pathway.
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CHAPTER 3.

ROLE OF BHLHE40 IN BREAST CANCER METASTASIS
Introduction

One in every eight women in the United States will be diagnosed with breast
cancer over the course of her lifetime [118]. An estimated 266,120 new cases are
expected, and 40,920 women are expected to die from breast cancer in 2018 in the United
States [118]. Distant metastasis is the major cause of breast cancer related deaths.
Hypoxia has been recognized as a primary driving force of distant metastasis of breast
cancer [19, 49, 119-122]. Among hypoxia responsive genes are both promoting and
suppressive factors for malignant progression. It is unclear how the expression and
activities of metastasis-promoting factors are preferentially augmented in metastatic
tumors. A large body of studies have focused on elucidating the molecular mechanisms
by which hypoxia enables cancer cells to survive a variety of stresses imposed during the
metastatic cascade, including nutrient depletion, loss of attachment and deprivation of
growth factors.
Hypoxia-induced exosomic secretion of cytokines and growth factors plays a key
role in promoting metastasis through both tumor autonomous and non-autonomous
mechanisms [123, 124]. Exosomes are microvesicles (40–130 nm) constitutively released
by a variety of cells into the extracellular environment to promote cell-to-cell
communication [125]. Tumor cells have been reported to utilize exosomes to transfer
nucleotides, lipids and proteins into surrounding cells or cells in distant metastatic niches
[125, 126]. Hypoxia is known to markedly increase the number of secreted exosomes, as
well as alter the contents of exosomes [127]. However, our understanding of the
regulation of exosome secretion is rudimentary.
Although the cellular response to hypoxia is mainly controlled by two basic helixloop-helix transcription factors, HIF1A and EPAS1/HIF2A, the outcomes of hypoxia
response are modified by other transcription regulators that are regulated by hypoxia or
interact with HIF1A or EPAS1 [128, 129]. This study focuses on the role of a basic helix
loop helix transcription factor BHLHE40 (also known as DEC1/ BHLHB2/ SHARP2/
STRA13) in metastasis of breast cancer. BHLHE40 expression is directly activated by
HIF1A in a variety of tumor cells under hypoxia [130, 131]. High BHLHE40 expression
has been linked to activation of hypoxia response pathway, elevated metastatic potentials
and poor prognosis of various types of tumors, including hepatocellular carcinoma,
pancreatic cancer and invasive breast cancer [132-134]. It is reported that BHLHE40
binds to the E-box elements and regulates the expression of genes associated with
circadian rhythm, cell differentiation, cell senescence, lipid metabolism, DNA damage
response and immune response [135-138].
However, the action mechanism and downstream targets of BHLHE40 in breast
cancer cells are largely unknown. In this study, we provide evidence that BHLHE40 is a
pro-metastasis factor in breast cancer cells that promotes tumor cell survival and
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migration by modulating exosomic secretion of HBEGF, a heparin binding epidermal
growth factor.
Methods
Cell culture
Breast cancer MDA-MB-231 and MCF7 cells were obtained from ATCC
(Manassas, VA, USA) and maintained in Minimal Essential Medium (ThermoFisher
Scientific, Rockford, IL, USA) supplemented with 10% fetal bovine serum (FBS), 200
U/ml of penicillin-streptomycin and 0.5 g/ml amphotericin B (Cellgro, Manassa, VA,
USA). A lung metastatic derivative of MDA-MB-231 (LM) and a tamoxifen-resistant
derivative of MCF7 (TR) were established as described previously [139, 140]. A stable
line (BHLHE40-KD) expressing a short hairpin RNA against BHLHE40
(TRCN0000232187, Sigma-Aldrich, St Louis, MO, US) were generated by lentiviral
transduction and selected in medium containing 2 g/ml puromycin (Sigma-Aldrich). A
colony of BHLHE40 knockout variant (BHLHE40-KO) of MDA-MB-231 was generated
by using the CRISPR/Cas9 all-in-one expression system (HCP221270-CG01-1,
GeneCopoeia) and selected in medium supplemented with 500 g/ml of gentamicin. To
knockout HIF1A and EPAS1 by CRISPR/Cas9 editing, gRNA targeting exon 1 of HIF1A
or EPAS1 was individually cloned into the pX462-puromycin and pX462-hygromycin
vectors (expressing Cas9n, AddGene), respectively. MDA-MB-231 cells were transfected
with pX462-puro-HIF1A gRNAs using FuGene HD followed by selection in puromycin.
A clonal line that had no HIF1A protein detected by immunoblotting was transfected
with pX462-hygromycin-EPAS1 gRNA and selected by hygromycin. Hygromycinresistant colonies that had no EPAS1 detected by immunoblotting were pooled to
generate a HIF1A/EPAS1 double knockout (HIF-dKO) subline. For all KD or KO
sublines, control cells were transfected with corresponding empty vectors (EV) and
selected in antibiotics in parallel with cells transfected with shRNAs or gRNAs. Pooled
drug-resistant colonies of control cells were used as EV control lines.
Orthotropic xenograft and experimental lung metastasis models
All in vivo studies were performed in accordance with the protocols approved by
the Institutional Animal Care and Use Committee (IACUC) of the University of
Tennessee Health Science Center. NOD. Cg PrkdcscidIl2rgtm1Wjl/Szj (NSG) mice were
purchased from Jackson Laboratories (Bar Harbor, ME, USA). Orthotropic xenograft and
experimental lung metastasis (tail-vein injection) models were established by using
fluorescence labelled tumor cells, as previously described [95, 139]. Tumor size was
monitored and measured weekly using digital calipers. Tumor volume was calculated as:
volume = (width2 x length)/2. Lung metastasis was quantified by fluorescent imaging of
lungs and qPCR of human Alu DNA repeats (Forward primer: 5’:
GTCAGGAGATCGAGACCATCCC 3’, Reverse primer: 5’:
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TCCTGCCTCAGCCTCCCAAG 3’). Circulating tumor cells in whole blood (collected
by cardiac puncture) were isolated by using the Ficoll-Paque PLUS medium (GE
Healthcare Life Sciences, Piscataway, NJ, USA) and counted under fluorescent
microscope.
Migration, invasion and wound healing assays
Transwell membrane inserts with 8-micron pores (BD Biosciences, Bedford, MA,
USA), uncoated or coated with Matrigel, were used to determine the migratory and
invasive activities of cancer cells, respectively. Cells undergoing migration and invasion
were expressed as: Percent migration = mean number of cells migrating through the
uncoated transwell x 100 / mean number of seeded cells. Percent invasion = mean
number of cells migrating through the matrigel-coated transwell x 100 / mean number of
migrating cells through the uncoated pores). Real-time assessment of migratory activity
during scratch-wound healing was performed by using the IncuCyte ZOOM-ImageLock
plate system (Essen Bioscience, Michigan, USA). To examine the expression levels of
proteins in response to scratch wounds, the EMD Millipore Chemicon Cell Comb Scratch
assay kit (Millipore) was used to generate a high-density field of scratches in a confluent
cell monolayer to maximize the area of wound edges. To examine the effect of HBEGF
on cell migration and invasion, a neutralizing antibody of HBEGF (10 g/ml, AF-259NA, R&D systems, Minneapolis, MN, USA) or a HBEGF peptide (20 g/ml) was added
to the medium.
Suspension culture, viable cell counting and caspase assays
To mimic the loss of attachment, cells were cultured in PolyHEMA (Sigma
Aldrich) coated plates to prevent adherence. Methylcellulose (1%) was added into
medium to prevent formation of large cell aggregates to accurately measure tumor cell
proliferation in suspension. Viable cells were counted by Trypan Blue exclusion method.
Cell apoptosis was determined by using the caspase Glo 3/7 assay kit (Promega,
Madison, Wi, USA) or immunoblotting of cleaved Caspase 9.
Luciferase reporter assay for HIF activity
Luciferase reporter constructs driven by hypoxia responsive elements of LDHA
(LDHA-Luc, S721613) and ITGA6 (ITGA6-Luc, S708174) were purchased from
SwitchGear Genomics (Carlsbad, CA, USA). Cells (3x105) were transfected with 500ng
LDHA- or ITGA6-Luc and 10 ng CMV--Galactosidase (control for transfection
efficiency), along with 250ng of an empty vector or a HIF1A-expressing construct
(HsCD00444875, DNASU plasmid repository), by using Fugene6 (Promega). Forty-eight
hours after transfection the cells were exposed to hypoxia (1% O2) for six hours.
Luciferase and -gal activities were measured by using the LightSwitch Luciferase Assay
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System and Promega Beta-Glo Assay System, respectively. Relative luciferase activities
normalized to -gal were presented as: mean ± SD, n=6.
Exosome isolation and analysis
To isolate exosomes, 5x106 cells were cultured in medium supplemented with
exosome-free serum (SystemBio, Palo Alto, CA, USA). Exosomes in the conditioned
medium were purified by using the ExoQuick-TC solution (SystemBio), and quantified
under a fluorescent microscope after labeled with carboxyfluorescein diacetate
succinimidyl ester (CFSE) by using the Exo-Glow labeling kit (SystemBio) that is
designed to exclude background particles. To analyze the protein content, isolated
exosomes were lysed in RIPA buffer (Pierce, ThermoScientific) containing protease
inhibitor cocktail (SigmaAldrich) and subjected to immunoblot analysis. To examine the
effect of purified exosomes on cell migration, exosomes were re-suspended in exosomefree medium and added to cells seeded in Transwells to evaluate migration.
Gene expression microarray and qPCR analysis
Total RNA from cells exposed to hypoxia (1% O2 for 6 and 48h) was purified by
using the RNeasy kits (Qiagen) and submitted to the Molecular Resource Center at
University of Tennessee Health Science Center for labelling and hybridization to the HT12 expression BeadChips (Illumina, Chicago, IL, USA). Hybridization signals were
processed for annotation, background subtraction, quantile normalization and presence
call filtering by using the Gene Expression Module of the GenomeStudio Software
(Illumina). The microarray data can be found in the Gene Expression Omnibus database
with accession number of GSE107300 (secure token: wbafiwcgptkvjwf). Hypoxia
responsive genes were defined as genes whose expression was altered by ≥1.5 fold
(hypoxia vs. control) in two independent experiments. BHLHE40 target genes were
defined as genes whose expression was altered by ≥1.5 fold (BHLHE40-KD vs. EV) in
two independent experiments. To examine the effect of BHLHE40-KD on gene
expression in cells exposed to hypoxia (1% O2) in combination with low glucose (1 mM)
(1%O2/LG), a condition frequently encountered by cells in solid tumors, total RNAs of
cells exposed to (1%O2/LG for 4h from three independent experiments were pooled and
analyzed using the GeneChip Human Gene 1.0 ST array (Affymetrix, Santa Clara, CA,
USA). The Affymetrix data were extracted, normalized, and summarized with the robust
multi-average (RMA) method implemented in the Affymetrix Expression Console. To
validate microarray data by qPCR, total RNAs from cells in three independent
experiments with duplicates was prepared by using trizol (Life Technologies, Grand
Island, NY, USA). cDNA’s were synthesized using iScript cDNA Synthesis kits (BioRad, Hercules, CA, USA) and qPCR was performed on the CFX96TM Real-Time PCR
detection system by using SYBR green supermix (Bio-Rad). Expression data of mRNA
were normalized by the 2-ΔΔCT method to RPL13A and presented as mean ± standard
deviation (SD). Primers of qPCR were obtained from the Primerbank [141].

43

Protein extraction, co-immunoprecipitation and immunoblotting
For immunoblotting (IB) analysis, whole cell lysates and nuclear proteins were
prepared by using RIPA buffer supplemented with protease inhibitor cocktails (SigmaAldrich) and the NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo
Scientific), respectively. To detect protein-protein interaction, soluble proteins were
extracted by using the Pierce IP Lysis Buffer (Thermo Scientific) supplemented with
protease inhibitor cocktails and co-immunoprecipitation was performed by using the
TrueBlot Immunoprecipitation and Western Blot Kit (Rockland Immunochemicals Inc.,
Limerick, PA). IB signals were developed by using the SuperSignal West Dura Extended
Duration Substrate and the CL-XPosure Film (Thermo Scientific). Antibodies used in this
study were: anti-EGFR-Tyr1110P, anti-EGFR, anti-ERK1/2-Thr202/Tyr204P, antiERK1/2, anti-AKT-Tyr416P, anti-AKT, anti-Caspase9, anti-HDAC1 and anti-HDAC2
from Cell Signaling Technologies (Boston, MA, USA); anti-GAPDH from Millipore
(Merck, Darmstadt, Germany); anti-TBP from Abcam (Cambridge, MA, USA); antiCTGF from Abgent (San Diego, CA, USA); anti-HBEGF and anti-CD9 from R&D
Biosystems (Minneapolis, MN, USA); anti-BHLHE40, anti-HIF1A and anti-EPAS1 from
Novus Biologicals (Littleton, CO, USA); and anti-ALIX, anti-TSG101, anti-CD81 from
Santa Cruz (Dallas, TX, USA).
Chromatin immunoprecipitation
Protein-DNA crosslink, nuclear fraction extraction and chromatin fragmentation
were performed as described previously [95]. Soluble fraction of sheared chromatin (200500bp in length) was pre-cleaned with Magnabind Goat anti-Rabbit IgG (for antiBHLHE40 and anti-HDAC1) or Magnabind Goat anti-Mouse (for anti-HDAC2) (Life
Technologies), followed by immunoprecipitation with control IgG or antibodies against
BHLHE40, HDAC1 or HDAC2, and Magnabind beads conjugated with a secondary
antibody. DNA in the decrosslinked immunocomplexes was isolated with the MiniElute
PCR purification kit (Qiagen, Germantown, MD, USA). qPCR was performed to detect
the presence of proximal promoter region of HBEGF (-529 to -372 from the transcription
start site) by using the following primers: forward 5’ TGCCTGCAACTTCAACT CTG
3’ and reverse 5’ CCATCCCTGTCACCCTCTAA 3’.
Statistical analysis
Student’s t-tests, one-way ANOVA with post-hoc Tukey test and Pearson r
correlation significance analyses were performed by using the GraphPad Prism 5
software (Graphpad, San Deigo, CA, USA); p values <0.05 (*) were considered
statistically significant.
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Results
BHLHE40 knockdown leads to decreased primary tumor growth and lung
metastases
To define the role of BHLHE40 in breast cancer metastasis, we examined the
effect of its knockdown (KD) by a shRNA lentiviral construct on spontaneous lung
metastasis of orthotopic xenograft tumors derived from a lung metastasis-enriched
subline (LM) of breast cancer MDA-MB-231 cells [83]. The protein levels of BHLHE40
is significantly induced by hypoxia (1% O2, 16h). BHLHE40-shRNA expression
effectively reduced both baseline and hypoxia-induced levels of BHLHE40 in LM cells
(Figure 3-1A). In NSG mice inoculated with 2x105 control LM-EV (empty vector) cells
in the inguinal mammary gland fat pads, palpable tumors were detected at 2 weeks
(Figure 3-1B) and lung metastasis became evident at 5 weeks (Figure 3-1C) postinoculation. BHLHE40-KD delayed the onset of primary tumors, which became palpable
3 weeks after inoculation, and reduced the growth rate of primary tumors, coincident with
decreased lung metastases (Figure 3-1A, B, and C). To further investigate the effect of
BHLHE40-KD on lung metastases, primary tumors of EV and BHLHE40-KD cells were
surgically removed at 3 and 5 weeks post-inoculation, respectively, when they reached
similar size with a diameter of 4-5 mm. Lung metastasis was examined four weeks after
primary tumor resection (Figure 3-1D). BHLHE40-KD substantially reduced lung
metastasis in mice with similar primary tumor burdens. Taken together, these results
suggest that BHLHE40 plays a role in promoting primary tumor growth and spontaneous
distant metastasis of breast cancer cells.
BHLHE40 knockdown reduces lung colonization of tumor cells inoculated through
tail vein
To determine whether BHLHE40 regulates late metastatic events after entry of
tumor cells into blood stream, we examined the effect of BHLHE40-KD on the ability of
tumor cells to survive circulation and colonize in the lungs by using an experimental
metastasis model, in which tumor cells were delivered into blood stream through tail-vein
injection to bypass the initial steps of metastasis, namely, migration and intravasation.
LM-EV and LM-BHLHE40-KD cells (5 × 105) were injected into the left lateral tail-vein
of 5-week-old female NSG mice, and tumor cells in the bloodstream and lung tissues
were examined at various time-points post-injection (Figure 3-2). Compared to control
LM-EV cells, LM-BHLHE40-KD cells were more rapidly eliminated from the
bloodstream (Figure 3-2A). LM-EV cells were observed in lung tissues at 72 hours and
formed large metastatic foci at 4 weeks after tail vein injection (Figure 3-2B and C). In
contrast, BHLHE40-KD cells were not detected in lung tissue at 72h, and formed lower
metastatic foci in lungs than EV cells at various time points (Figure 3-2B and C). No
fluorescent loci of EV or BHLHE40-KD cells were found in other organs (i.e., livers,
spleens and kidneys) within 5 weeks after tail vein inoculation. Together, these results
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Figure 3-1. BHLHE40 knockdown (KD) significantly reduced primary tumor size
and lung metastatic burden in an orthotopic xenograft model.
A. BHLHE40-shRNA expression effectively reduced both baseline and hypoxia-induced
expression of BHLHE40 protein in the LM cells, as determined by Immunoblotting. B.
Orthotopic xenograft tumors derived from LM-BHLHE40-KD cells exhibited lower
growth rate than tumors derived from control LM EV (empty vector) cells. NSG mice
were inoculated in the inguinal mammary gland fat pads with 2x105 cells. Tumor size was
monitored and measured weekly by using a digital caliper. Tumor volume was calculated
as: volume = (width2 x length)/2. *p<0.05 (n=20, KD vs. EV at indicated time points),
One-way ANOVA followed by Tukey's post-hoc tests. C. Spontaneous lung metastasis
detected by fluorescent imaging of lungs or human ALU repeats qPCR 5-wk after
inoculation of tumor cells in mammary gland fat pads. *p<0.05 (n=10, KD vs. EV),
student’s t test. D. Lung metastasis in mice after resection of primary tumors. Primary
tumors in mammary gland fat pads were resected when they reached a size of 5 x 5 mm
and lung metastasis were analyzed 4 weeks post-resection by fluorescent imaging of
lungs or human ALU repeats qPCR. *p <0.05, (n=10, KD vs. EV), student’s t test.
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Figure 3-2. BHLHE40 knockdown (KD) reduced lung colonization of tumor cells
inoculated into the circulation via tail veins.
A. Less tumor cells were detected in blood of NSG mice inoculated via tail vein injection
with LM BHLHE40-KD than mice inoculated with empty vector control LM EV cells.
Tumor cells in whole blood collected by cardiac puncture at indicated times after tail vein
injection were isolated by using the Ficoll-Paque PLUS medium and counted under
fluorescent microscope. *p<0.05 (n=3, KD vs. EV), One-way ANOVA followed by
Tukey's post-hoc tests. B. Fluorescent imaging of metastatic foci in lungs at different
time points post tail-vein injection. C. Percentage of areas occupied by metastatic loci in
the lungs, as quantified by fluorescent imaging and ImageJ. *p<0.05, (n=3, KD vs. EV),
One-way ANOVA followed by Tukey's post-hoc tests.
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suggest that BHLHE40 is required for tumor cells to survive circulation and establish
metastatic foci in the lungs.
BHLHE40 acts to promote cell migration, invasion and survival
Having established a role of BHLHE40 in distant metastasis of breast cancer cells
in vivo, we sought to identify the specific cellular processes that require BHLHE40
activity. Despite the significant effect of BHLHE40-KD on primary tumor growth and
lung metastasis of LM cells in vivo, BHLHE40-KD showed no significant effect on
proliferation of LM cells under normal 2-D growth conditions in vitro. The doubling
times, determined by trypan blue exclusion-based cell counting (daily for 7 days), of LMEV and LM-BHLHE40-KD cells were 36.37 ± 0.49 h (n=6) and 38.95 ± 3.61 h (n=6),
respectively. Therefore, we focused on investigating whether BHLHE40 is a downstream
effector of HIF1A activation by hypoxia or loss of attachment. Detached breast cells were
reported to rely on HIF1A activation to survive under normoxia [142]. In vitro cell
migration and invasion assays showed that BHLHE40-KD reduced the ability of cells to
penetrate either uncoated or matrigel-coated transwells under hypoxia condition (1% O2,
Figure 3-3A). Under the non-adherent culture condition for 15 days, in which cells were
mixed with growth medium supplemented with 1% methylcellulose to prevent cell
aggregation and then seeded in plates coated with polyHEMA to prevent adherence, the
number of viable LM BHLHE40-KD cell was significantly lower than LM EV cells
(Figure 3-3A, lower panel). To examine whether the effects exerted by BHLHE40-KD
on LM cells can be extended to the parent MDA-MB-231 cells, we established a
BHLHE40 knockout (KO) subline by using the CRISPR/Cas9 editing system. BHLHE40
protein depletion in the KO subline under normoxia or hypoxia was confirmed by
immunoblotting (Figure 3-3B, upper panel). BHLHE40-KO resulted in reduced number
of viable cells after a 15-day suspension culture in plates coated with polyHEMA to
prevent attachment (Figure 3-3B, middle panel), while showed no significant effect on
number of viable cells after a 5-day adherence culture. In addition, BHLHE40-KO
significantly sensitized MDA-MB-231 cells to apoptosis induced by hypoxia in
combination with glucose depletion (1%O2/GF, 6h), as evidenced by the appearance of
apoptotic morphology and activation of caspase3/7 (Figure 3-3B, lower panel).
We further examined the function of BHLHE40 in breast tumor cells with
elevated baseline activation of HIF1A and BHLHE40 by using the tamoxifen-resistant
(TR) and fulvestrant-resistant (FR) variants of MCF7 cells [140]. As shown in Figure 33C, mRNA expression levels of BHLHE40 and HIF1A are significantly elevated in TR
and FR cells in comparison to parent MCF7 cells. BHLHE40-KD in TR cells
substantially increased apoptosis induced by glucose depletion, under both normoxia and
hypoxia conditions, as well as reduced number of viable cells after a 15-day suspension
culture in polyHEMA-coated plates (Figure 3-3C). Collectively, these observations
provide evidence supporting a role of BHLHE40 in promoting survival and migration.

48

Figure 3-3.

BHLHE40 depletion impaired cell migration, invasion and survival.

A. BHLHE40 knockdown (KD) by shRNA in LM cells reduced cell migration and
invasion, as well as the number of viable cells during suspension culture in comparison to
LM EV cells. Migratory and invasive activities were determined by using Transwells,
uncoated or coated with Matrigel, respectively. Suspension culture was conducted by
seeding cells in medium containing 1% Methylcellulose and in dishes coated with
PolyHEMA for 15 days. *p <0.05 (n=6, KD vs. EV), student’s t test. B. BHLHE40
knockout (KO) by CRISPR/Cas9 editing in MDA-MB-231 cells reduced the number of
viable cells after suspension culture and enhanced apoptosis induced by hypoxia
combined with glucose depletion (1%O2/GF). Viable cells were determined by trypan
blue exclusion-based cell counting after a 15-day suspension culture. Apoptosis of cells
exposed to 1%O2/GF for 6h was examined by the appearance of apoptotic morphology
(as indicated by arrows in the cell images) and Caspase3/7 assays. *p <0.05 (n=6, KO vs.
EV), One-way ANOVA followed by Tukey's post-hoc tests. C. BHLHE40-KD by
shRNA in tamoxifen-resistant subline of MCF7 (TR) reduced the ability of cells to
survive 1%O2/GF (6h) and reduced number of viable cells after a 15-day suspension
culture. Elevated expression of HIF1A and BHLHE40 in TR and Fulvestrant-resistant
(FR) sublines of MCF7 cells were detected by qPCR. BHLHE40-KD was confirmed by
immunoblotting. Apoptosis induced by 1%O2/GF (6h) was determined by Caspase3/7
assays. Number of viable cells after a 15-day suspension culture was determined by
trypan blue exclusion-based cell counting. **P<0.05 (n=6, TR or FR vs. parent MCF7),
*p<0.05 (n=6, KD vs. EV), One-way ANOVA followed by Tukey's post-hoc tests.
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BHLHE40 is required for transcription activation of a set of cytokines and growth
factors
To delineate the molecular pathways regulated by BHLHE40, we performed
global gene expression analysis of LM-EV and LM BHLHE40-KD cells exposed to
hypoxia (1% O2, 6h or 48h). The microarray data can be found in the Gene Expression
Omnibus database with accession number of GSE107300. Overall, the expression levels
of 521 and 646 genes in LM-EV cells were altered (fold change ≥1.5 in two independent
experiments) by hypoxia at 6h and 48h, respectively. BHLHE40-KD abolished the
hypoxia-mediated upregulation of 45 (out of 261, 17.2%) and 98 (out of 361, 27.1%)
genes at 6h and 48h, respectively. In addition, BHLHE40-KD abolished the hypoxiamediated downregulation of 30 (out of 260, 10.5%) and 44 (out of 285, 15.4%) genes at
6h and 48h, respectively. The hypoxia-induced genes that were affected by BHLHE40KD were overrepresented by genes that encode proteins with cytokine or growth factor
activities as defined by Gene Ontology annotation (GO:0005125 and GO:0008083,
Fisher’s exact p <0.0001) (Figure 3-4A). The expression of a subset of these genes was
also reduced in BHLHE40-KD cells exposed to 1%O2/LG for 4h, compared to EV cell
(Figure 3-4B). In contrast, hypoxia-induced expression of a panel of the core hypoxia
responsive genes that are known to be directly targeted by HIF1A [129] was not
significantly affected by BHLHE40-KD (Figure 3-4C). These observations suggest that
BHLHE40-KD preferentially reduced hypoxia-induced expression of a set of cytokines
and growth factors, but did not cause a global defect in HIF1A-mediated transcription
activation. To confirm this notion, we examined the effect of BHLHE40-KO on HIFmediated expression of reporter luciferase driven by well-characterized HIF1A-binding
sites in the promoter regions of LDHA and ITGA6 [26-28]. As showed in Figure 3-4D,
BHLHE40-KD exhibited no significant effect on hypoxia-induced luciferase activities, in
the absence or presence of exogenous HIF1A protein. The effect of BHLHE40-KD on
expression of cytokines and growth factors in cells exposed to 1%O2/LG (4h) was
validated by qPCR (Figure 3-4E). Consistent with results in BHLHE40-KD cells
cultured in vitro, we detected reduced expression of connective tissue growth factor
(CTGF) and HBEGF, at both mRNA and protein levels, in the LM-BHLHE40-KD
primary tumors in comparison to LM-EV tumors established in mouse mammary gland
fat pads (Figure 3-4F).
To determine whether BHLHE40-mediated expression of genes encoding
cytokine or growth factors is relevant to clinical samples, we analyzed the mRNA
expression data of breast tumors in the TCGA database [109, 143]. The expression of
71.4 % (20 out of 28) of these BHLHE40-dependent genes (as showed in Figure 3-4A)
was found to be positively correlated with BHLHE40 expression with statistical
significance (p <0.05) in at least one of the four major subtypes of breast tumors (Table
3-1). This observation provides supporting evidence for a role of BHLHE40 in the
expression of these genes in human breast tumors.
Since hypoxia-induced cytokines and growth factors are commonly exported to
extracellular space by exosomes [144], we sought to determine whether BHLHE40-KD
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Figure 3-4. BHLHE40 knockdown reduced hypoxia-induced expression of a panel
of cytokines and growth factors.
A. Heatmaps of cytokines and growth factors whose hypoxia-induced expression (1% O2
at 6h or 48h, fold change ≥ 1.5 in two independent experiments) was diminished by
BHLHE40-knockdown (KD) in LM cells. The gene expression levels were determined
by using the Illumina Human HT-12 expression BeadChips. Normalized (Quantile
normalization) hybridization signals were log2 transformed and standardized by genes
across experiment conditions to generate heatmap. B. Heatmaps of a subset of genes list
in A whose expression was affected by BHLHE40-KD in LM cells exposed to hypoxia
combined with low (1mM) glucose (1%O2/LG, 4h). The gene expression levels were
determined by using the Affymetrix Human Gene 1.0 ST array. C. Heatmaps of hypoxiainduced genes whose expression was not significantly affected by BHLHE40-KD in LM
cells as determined the Illumina Human HT-12 expression BeadChips. D. Expression of
luciferase reporters driven by hypoxia-responsive elements of ITGA6 or LDHA was not
affected by BHLHE40 knockout (KO) by CRISPR/Cas9 editing in MDA-MB-231 cells,
in the absence or presence of exogenous HIF1A. Luciferase activities were normalized to
co-transfected CMV--galactosidase and presented as mean±SD (n=6). E. Expression of
genes in control LM EV and LM BHLHE40-KD cells exposed to 1%O2/LG (4h). mRNA
expression levels were determined by qPCR, normalized to RPL13A, and presented as
mean±SD (n=6). *p<0.05 (n=6, 1%O2/LG vs. untreated control), **p<0.05 (n=6, KD vs.
EV), One-way ANOVA followed by Tukey's post-hoc tests. F. mRNA and protein
expression levels of HBEGF and CTGF in primary xenograft tumors, determined by
qPCR and immunoblotting, respectively. *p<0.05 (n=6, KD vs. EV), Student’s t test.
Representative Immunoblotting images of 3 tumors of KD or EV cells were presented.
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Table 3-1.
Correlated expression of BHLHE40 and its putative targets in breast
tumors (TCGA).
BL (n=230)
Gene
CCL3L1
CMTM3
CMTM7
CMTM8
CSPG5
CTGF
EBI3
EDN1
FGF1
FGF13
FLT3LG
GMFG
HBEGF
IL11
IL12A
IL15
IL17A
IL1A
IL25
IL32
JAG2
MDK
NAMPT
NRTN
TFF1
TNFSF12
VEGFB
VEGFC

Her2 (n=162)

LA (n=315)

LB (n=300)

Pearson
r value

P value

Pearson
r value

P value

Pearson
r value

P value

Pearson
r value

P value

0.1210

0.0694

-0.2045

0.0095

0.0504

0.3792

0.0480

0.4136

-0.0042

0.9494

0.0358

0.6510

0.5065

< 0.0001

-0.0521

0.3687

-0.2761

< 0.0001

-0.0697

0.3780

0.2516

< 0.0001

0.0635

0.2729

-0.1580

0.0165

-0.0886

0.2624

0.1034

0.0670

-0.0013

0.9817

-0.1333

0.0435

-0.0309

0.6961

-0.0351

0.5345

-0.0504

0.3850

0.0203

0.7593

0.3087

< 0.0001

0.4876

< 0.0001

0.0631

0.2760

0.2135

0.0011

-0.2060

0.0085

0.0805

0.1543

-0.0271

0.6402

0.0705

0.2867

0.0928

0.2401

0.3805

< 0.0001

0.0273

0.6379

0.1666

0.0114

0.2470

0.0015

0.4225

< 0.0001

0.0357

0.5384

-0.1105

0.0946

-0.1782

0.0233

0.1393

0.0134

-0.1276

0.0271

0.2436

0.0002

-0.0588

0.4573

0.2878

< 0.0001

-0.0264

0.6487

0.2593

< 0.0001

-0.1764

0.0247

0.3367

< 0.0001

-0.1271

0.0277

0.3871

< 0.0001

0.2873

0.0002

0.3254

< 0.0001

0.1577

0.0062

0.1413

0.0322

0.1762

0.0249

0.2053

0.0002

0.0328

0.5710

0.0325

0.6207

-0.0582

0.4618

-0.1035

0.0649

-0.1543

0.0069

0.3407

< 0.0001

0.0628

0.4273

0.1632

0.0037

-0.0913

0.1146

0.1036

0.1139

0.0845

0.2850

-0.0221

0.6942

-0.0919

0.1094

0.2140

0.0013

-0.0057

0.9440

0.0399

0.4960

-0.0720

0.2359

-0.1011

0.3633

0.0560

0.6578

-0.1569

0.0293

0.1617

0.0661

0.1597

0.0153

-0.0571

0.4704

0.3242

< 0.0001

-0.0473

0.4141

-0.0418

0.5287

0.0387

0.6250

0.0880

0.1190

-0.0167

0.7729

-0.0837

0.2057

-0.0947

0.2305

0.1107

0.0496

0.0066

0.9099

0.2678

< 0.0001

0.0873

0.2691

0.1667

0.0030

-0.1819

0.0016

-0.4457

< 0.0001

-0.0350

0.6596

0.0672

0.2411

-0.0288

0.6220

0.2156

0.0009

-0.0148

0.8516

0.0221

0.6936

-0.1243

0.0300

0.1690

0.0102

-0.0271

0.7323

0.1482

0.0084

0.0565

0.3296

-0.0460

0.4879

0.0811

0.3049

0.2028

0.0003

0.0443

0.4449

0.3664

< 0.0001

0.1760

0.0251

1.0000

< 0.0001

-0.0922

0.1110

HBEGF expression is significantly correlated with BHLHE40 in basal-like, Her2positive, Luminal A, and Luminal B subtypes of breast cancer. The correlation analysis
was performed using the mRNA expression Z-scores (RNA Seq V2 RSEM, TCGA). BL,
basal-like; Her2, ERBB2-enriched; LA, Luminal A; LB, Luminal B. (Highlighted cells
show significant positive correlation)
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could affect exosome secretion. As shown in Figure 3-5, the numbers of isolated
exosomes were significantly reduced in the conditioned medium from MDA-MB-231
BHLHE40-KO and TR-BHLHE40-KD cells in comparison to the corresponding control
cells cultured under both normal condition or exposed to 1%O2/LG for 6h. The presence
of exosomic markers (i.e., CD9, CD81, ALIX and TSG101) [145, 146]) in the isolated
exosomes was confirmed by immunoblotting (Figure 3-5). BHLHE40 depletion reduced
protein levels of HBEGF in the purified exosomes (Figure 3-5), reflecting the reduced
levels of HBEGF mRNA and HBEGF protein in whole cell extracts of BHLHE40-KD or
KO cells (Figure 3-4E and Figure 3-5). These observations suggest that BHLHE40depletion reduced exosome secretion because of reduced expression of cytokines and
growth factors.
BHLHE40 activates HBEGF transcription by sequestering HDAC1 and HDAC2
from promoter binding
Among the cytokines and growth factors affected by BHLHE40-KD in LM cells,
the expression level of HBEGF mRNA is positively correlated with the expression level
BHLHE40 mRNA in all four major subtypes of breast tumors in the TCGA database
(Figure 3-4, Figure 3-5 and Table 3-1). HBEGF is a heparin-binding EGF-like growth
factor that promotes cell proliferation and invasion through EGFR activation [147]. To
examine the molecular mechanism underlying BHLHE40-mediated HBEGF
transcription, we performed ChIP analysis. BHLHE40 binding to the proximal promoter
region of HBEGF was not affected by 1%O2/LG (data not shown), indicating that
HBEGF transcription activation was not caused by increased BHLHE40-DNA binding.
However, 1%O2/LG treatment reduced binding of HDAC1 and HDAC2 to the HBEGF
promoter (Figure 3-6A), which is coincident with increased BHLHE40-HDAC1/2
interaction in the soluble cellular fraction, as detected by reciprocal Coimmunoprecipitation (CoIP) followed by immunoblotting (IB) (Figure 3-6B). In cells
lacking BHLHE40, HDAC1/HDAC2 remained bound to the promoter region of HBEGF
after 1%O2/LG treatment (Figure 3-6A). This result suggests that BHLHE40 plays a role
in facilitating dissociation of HDAC1/2 from promoters through protein-protein
interaction. To examine whether HDAC1/2-DNA binding plays a key role to suppress
transcription of BHLHE40 target genes, we examine the effect of HDAC inhibitors on
mRNA expression of HBEGF, CTGF and VEGFC. As shown in Figure 3-6C, both
HDAC2-specific (BRD6688, 10 M) and pan-HDAC inhibitor (TSA, 2M) increased
expression of BHLHE40 target genes in MDA-MB-231 EV and BHLHE40-KD cells,
supporting a role of HDAC1/2 in suppressing transcription of BHLHE40 target genes.
Taken together, these observations suggest that sequestering HDAC1/2 from DNA
binding contributes to BHLHE40-mediated transcription activation.
HBEGF acts to promote cell survival and migration
To examine whether BHLHE40-driven HBEGF expression plays a role in EGFR
activation to promote cell survival, we examined the phosphorylation status of EGFR and
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Figure 3-5. Exosomic secretion of HBEGF was reduced by BHLHE40 depletion in
MDA-MB231 or TR cells.
A. BHLHE40-KO by CRISPR/Cas9 editing in MDA-MB-231 cells reduced the total
number of exosomes and the amount of HBEGF protein in exosomes in comparison to
empty vector control EV cells. B. BHLHE40 knockdown (KD) by shRNA in TR cells
reduced the total number of exosomes and the amount of HBEGF protein in exosomes in
comparison to TR EV cells. Exosomes were purified from conditioned medium of 5x106
cells cultured in medium supplemented with exosome-free serum, either under normal
culture condition or exposed to 1%O2/LG for 6h. Exosomes were purified by using the
ExoQuick-TC solution and quantified under a fluorescent microscope after labeled with
carboxyfluorescein diacetate succinimidyl ester (CFSE) by using the Exo-Glow labeling
kit, which is designed to exclude background particles. Exosome number in the bar graph
is presented as mean number of exosomes per field ± SD (total 9 fields from three
independent experiments were examined). The presence of HBEGF and exosome
markers in purified exosomes (3 g protein/lane) or whole cell extracts (WCE, 30 g
protein/lane) were detected by immunoblotting. **P<0.05 (n=9, 1%O2/LG vs. control),
*p <0.05 (n=9, KO or KD vs. EV), One-way ANOVA followed by Tukey's post-hoc
tests.
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Figure 3-6. BHLHE40 activates gene expression by sequestering HDAC1 and
HDAC2 from genome DNA binding in MDA-MB-231 cells exposed to hypoxia and
low glucose (1%O2/LG, 4h).
A. BHLHE40-knockout (KO) diminished dissociation of HDAC1 and HDAC2 from the
promoter region of HBEGF in MDA-MB-231 cells exposed to 1%O2/LG (4h), as
determined by chromatin immunoprecipitation (ChIP) followed by qPCR of the HBEGF
promoter region (-529 to -372 from the transcription start site). HBEGF promoter binding
activity of HDAC1 or HDAC2 was calculated as: [(DNA amount in anti-HADC IP
complex - DNA amount in control IgG IP complex)/DNA amount in 1% input]. *p<0.05
(n=6, 1%O2/LG vs. control), **p<0.05 (n=6, KO vs. EV). B. 1%O2/LG treatment
increased interactions between BHLHE40 and HDAC1/2 in the soluble cellular fraction
of MDA-MB-231 EV cells. Protein-protein interaction was detected by reciprocal coimmunoprecipitation (IP)/immunoblotting (IB) analysis. C. HDAC inhibition induced
expression of BHLHE40 target genes. Cells were exposed to hypoxia (1% O2) or HDAC
inhibitors (BRD6688 10M or TSA 2M) for 24 h. mRNA expression levels were
determined by qPCR, normalized to RPL13A, and presented as mean±SD (n=6). *p
<0.05 (n=6, treated vs. untreated control cells), One-way ANOVA followed by Tukey's
post-hoc tests.
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its downstream targets in MDA-MB-231 and TR sublines exposed to 1%O2/GF for 6 h, a
condition known to induce apoptosis as showed in Figure 3-3. Compared to cells with
intact BHLHE40 activity, MDA-MB-231-BHLHE40-KO and TR-BHLHE40-KD cells
expressed lower levels of HBEGF mRNA and protein, which was coincident with
reduced levels of phosphorylation of EGFR, AKT and ERK and increased caspase 9
cleavage (Figure 3-7A and B). Next, we examined whether active HBEGF peptide could
rescue MDA-MB-231-BHLHE40-KO cells from apoptosis. As shown in Figure 3-7C,
addition of HBEGF peptide into culture medium of cells exposed to 1%O2/GF
significantly reduced activation of caspase 3/7. These observations provide evidence
supporting a role of HBEGF in promoting cell survival.
Monolayer scratch was found to induce expression of HIF1A, BHLHE40 and
HBEGF in MDA-MB-231-EV cells (Figure 3-8A), implicating a role of the HIF1ABHLHE40-HBEGF axis in cell migration during wound healing. By using the IncuCyte
ZOOM-ImageLock plate system, we demonstrated that BHLHE40-KO substantially
diminished the ability of MDA-MB-231 cells to close the wound gaps, which was
restored by addition of HBEGF peptide (Figure 3-8B and C). In contrast, a HBEGF
neutralizing antibody [148] inhibited wound healing of LM-EV cells (Figure 3-8B and
C). To confirm that exosomic HBEGF plays a key role in promoting cell migration, we
examined the migratory activities of MDA-MB-231 BHLHE40-KO cells in the presence
of conditioned medium or purified exosomes, which were collected from the MDA-MB231 EV cells at 24 h after extensive wound scratch. The Transwell migration assay
showed that both conditioned medium and purified exosomes from the wounded EV cells
increased the migratory activity of BHLHE40-KO cells (Figure 3-8D). Together, these
observations suggest that HBEGF act downstream of BHLHE40 to promote cell
migration.
To confirm that BHLHE40 and HBEGF are key downstream effectors of HIFs in
promoting cell migration, we examined the effect of BHLHE40 overexpression on a
HIF1A/EPAS1 double knockout subline (MDA-MB-231 HIF-dKO). Although HIF1A
mRNA expression level is approximately 6-fold higher than EPAS1 mRNA in MDAMB-231 cells according to reported RNAseq data (GSE73526), compensatory activation
of EPAS1 could compromise the effect of HIF1A knockout. Therefore, we used HIFdKO cells to examine whether BHLHE40 overexpression can rescue molecular and
phenotypic changes caused by HIF-KO. Gene expression analysis by qPCR showed that
HIF-dKO reduced baseline and 1%O2/LG induced expression of BHLHE40, HBEGF,
CTGF and VEGFC mRNAs, which was restored by BHLHE40 overexpression (Figure
3-9A). In addition, BHLHE40 overexpression reduced cell-cell contact, as showed by cell
imaging, and increased migratory activity of HIF-dKO cells, as determined by transwell
assays (Figure 3-9B). Immunoblotting analysis confirmed that BHLHE40 overexpression
restored expression levels of HBEGF protein in HIF-dKO cells exposed to 1%O2/LG
(Figure 3-9C). Together, these observations support the notion that BHLHE40 and
HBEGF act as key downstream effectors of HIFs to promote cell migration.
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Figure 3-7. BHLHE40 depletion reduced phosphorylation of EGFR, while
increased Caspase 9 cleavage, in cells exposed to glucose depletion and hypoxia
(1%O2/GF).
A. BHLHE40 knockout (KO) by CRISPR/Cas9 editing in MDA-MB-231 and BHLHE40
knockdown (KD) by shRNA in TR cells diminished HBEGF induction by 1% O2/GF
(6h). mRNA expression levels were determined by qPCR, normalized to RPL13A, and
presented as mean±SD (n=6). *p<0.05 (n=6, 1%O2/GF vs. control), **p <0.05 (n=6, KO
vs. EV), One-way ANOVA followed by Tukey's post-hoc tests. B. BHLHE40 depletion
reduced EGFR activation, as indicated by reduced phosphorylation of EGFR and its
downstream targets (ERK and AKT), while increasing apoptosis, as indicated by
detection of cleaved caspase 9. Data from three independent immunoblotting analyses are
presented. C. HBEGF peptide (10g/ml) reduced apoptosis induced by 1%O2/GF (6h) in
MDA-MB-231 BHLHE40-KO cells. Apoptosis was determined by Caspase 3/7 assays.
*p<0.05 (n=6, 1%O2/GF vs. control), **p <0.05 (n=6, HBEGF vs. untreated with
HBEGF), One-way ANOVA followed by Tukey's post-hoc tests.
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Figure 3-8. HIF-BHLHE40-HBEGF axis plays a role in promoting cell migration
during wound healing.
A. Monolayer scratch increased protein levels of HIF1A, BHLHE40 and HBEGF in
MDA-MB-231 EV cells. Intensive scratch wounds were generated by using the EMD
Millipore’s Cell Comb scratch assay kit and immunoblotting was performed 6h after cells
cultured under normoxia (19% O2) or hypoxia (1% O2). B. BHLHE40 knockout (KO) by
CRISPR/Cas9 editing reduced the migratory activity of MDA-MB-231 cells, which was
restored by addition of HBEGF peptide into the culture medium. In contrast, a HBEGF
neutralizing antibody reduced the migratory activity of MDA-MB-231-EV cells. Realtime assessment of migratory activity after wound scratch was performed by using the
IncuCyte ZOOM-ImageLock plate system. *P<0.05 (n=6, time points 6-24h, HBEGF vs.
untreated), **p<0.05 (n=6, time points 6-24h, anti-HBEGF vs. untreated), One-way
ANOVA followed by Tukey's post-hoc tests. Representative data from two independent
experiments with 6 replicates are presented. C. Images of representative wound fields at
0 and 24 h after wound scratch as described in B. D. Conditioned medium or purified
exosomes from MDA-MB-231-EV cells (24 h after wound scratch) increased migratory
activities of MDA-MB-231 BHLHE40-KO cells, as determined by the transwells
migration assays. The migrated cells in six fields were imaged and counted under
fluorescent microscope. The results were presented as: Percent migration = mean number
of cells migrating through the uncoated transwells x 100/mean number of seeded cells;
*p<0.05 (n=12, vs. untreated control), One-way ANOVA followed by Tukey's post-hoc
tests.
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Figure 3-9. Effect of BHLHE40 overexpression on molecular and phenotypic
changes caused by HIF1A/EPAS1 double knockout (HIF-dKO) in MDA-MB-231
cells.
A. BHLHE40 overexpression restored baseline and hypoxia/low glucose (1% O2/LG (6h)
induced expression of HBEGF, CTGF, TNFSF12 and VEGFC in in HIF-dKO cells. The
expression levels of mRNAs were determined by qPCR, normalized to RPL13A and
presented as mean±SD (n=6). *p<0.05 (n=6, vs. untreated HIF-dKO), **p<0.05 (n=6, vs.
HIF-dKO exposed to 1% O2/LG for 6h), One-way ANOVA followed by Tukey's posthoc tests B. BHLHE40 overexpression decreased cell-cell contact (as showed by the cell
images) and increased migratory activity of HIF-dKO cells exposed to 1% O2/LG (24h).
Migratory activity was determined by Transwell assays and presented as meant of
percentage of migrating cells ± SD (n=6). *p<0.05 (n=6, HIF-dKO vs. control wild-type
cells), **p<0.05 (n=6, HIF-dKO/BHLHE40 overexpression vs. HIF-dKO), One-way
ANOVA followed by Tukey's post-hoc tests. C. BHLHE40 overexpression restored
expression of HBEGF proteins in HIF-dKO cells exposed to 1% O2/GF (6h). Proteins
were detected by immunoblotting. GAPDH and TBP were used as loading control for
whole cell extract (WCE) or Nuclear extract (NE), respectively.
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High expression of BHLHE40 and HBEGF is associated with poor prognosis of
breast cancer
Having established a role of the BHLHE40-HBEGF axis in enhancing cell
survival and migration, we sought to examine the association of BHLHE40 and HBEGF
with clinical characteristics of breast tumors by using the gene expression data in the
Kaplan Meier plotter database, which contains the Affymetrix microarray expression data
of 2,178 breast cancer patients [108]. We found that high expression of BHLHE40 or
HBEGF is significantly associated with shorter interval of relapse free survival (RFS)
among patients diagnosed with triple-negative breast cancer (TNBC, n=255) and patients
treated with chemotherapy (n=602) (Figure 3-10). However, BHLHE40 and HBEGF are
not poor prognostic markers for patients with estrogen receptor positive tumors or
patients treated with endocrine therapy. In addition, we analyzed the association of
BHLHE40 and HBEGF with overall survival (OS) of TNBC by using the METABRIC
dataset in the cBioPortal for Cancer Genomics (Breast Cancer, METABRIC). High
BHEGF expression was found to be associated with short interval of OS (Figure 3-10C).
Although TNBC with higher expression of BHLHE40 tends to have a shorter interval of
OS, this correlation did not reach statistical significance (Figure 3-10C). These findings
suggest that activation of the BHLHE40-HBEGF pathway contributes to aggressive
behaviors of TNBC and chemoresistance.
Discussion
Breast cancer metastasis is the major cause of fatality in breast cancer patients.
Adaptation to hypoxia is a driving force of metastatic progression and drug resistance
[120]. Proteins secreted by tumor cells under hypoxia promote metastasis by altering
tumor cell behaviors and modifying the tumor microenvironment [119]. Therefore, the
regulation of hypoxia-driven protein secretion is currently under intense investigation.
This study, reports a novel role of BHLHE40, a transcription factor directly targeted by
HIF1A, in regulating exosomic release of HBEGF. Our results suggest that the HIFBHLHE40-HBEGF axis constitutes an important signaling mechanism to promote
metastasis of breast tumors.
Exosomes are 40-100 nm vesicles that originate from the endocytic compartment.
Exosomes contain a wide range of proteins, lipids, mRNAs and microRNAs (miRNAs)
that reflect the molecular contents of the parental cells [144]. Compared to normal cells,
cancer cells exhibit higher activity of exosome secretion, which is further augmented by
stress conditions, including TP53 activation, alteration of intracellular calcium levels,
senescence, hypoxia and acidosis [149]. Exosomes released by tumor cells have been
reported to contain cytokines and growth factors that promote metastasis and
chemoresistance [149-151]. However, the precise molecular mechanism governing the
release of exosomes remains elusive. This study however, suggests that BHLHE40 acts
as a key downstream effector of HIFs to activate transcription and subsequent exosome
secretion of a set of cytokines and growth factors.
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Figure 3-10. High expression of BHLHE40 and HBEGF is associated with poor
prognosis of breast cancer.
A. High expression of BHLHE40 and HBEGF is associated with short interval of relapse
free survival (RFS) of patients diagnosed with triple-negative breast cancer (TNBC,
n=255). The gene expression data and patient information were obtained from the
Kaplan-Meier plotter database. B. High expression of BHLHE40 and HBEGF is
associated with short interval of RFS among patients treated with chemotherapy (n=602).
The gene expression data and patient information were obtained from the Kaplan-Meier
plotter database. C. High expression of HBEGF is associated with short interval of
overall survival (OS) of patients diagnosed with TNBC (n= 150). The gene expression
data and patient information were obtained from the cBioPortal for Cancer Genomics
(Breast Cancer, METABRIC, Nature 2012 & Nat Commun 2016).
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BHLHE40 was previously described as a transcriptional repressor that binds to
the class B E-box (CACGTG) and recruits HDAC1 and HDAC2 to block transcription
[152]. BHLHE40 activation has been linked to cell cycle arrest, senescence,
differentiation and apoptosis [153-155]. On the other hand, emerging evidence supports a
role of BHLHE40 in transcription activation and promoting cell survival. For instance,
BHLHE40 was reported to activate transcription of pro-survival factors in tumor cells,
including BIRC5 and DeltaNp63 [156, 157]. In addition, BHLHE40 was reported to
activate the transcription of a panel of cytokines required for activation of murine CD4+
T cells [117, 158]. It remains undefined what factors determine the selectivity of
BHLHE40 to suppress or activate transcription. The BHLHE40-mediated transcription
activation of DeltaNp63 was shown to depend on its direct interaction with HDAC2
[156]. In agreement with this observation, our results suggest that BHLHE40 activates
HBEGF transcription by sequestering HDAC1/2 from DNA binding. It remains to be
determined whether interfering with HDAC1/2-DNA binding is a general mechanism
responsible for BHLHE40-mediated transcription activation.
Elevated EGFR activation is known to promote survival, proliferation and
invasion of tumor cells under hypoxia, and multiple mechanisms have been linked to
hypoxia-induced EGFR activation [159]. For example, EPAS1 activation by hypoxia was
shown to increase EGFR mRNA translation [160]. Hypoxia-mediated activation of
metalloproteases (e.g., ADAM12 and ADAM17) was reported to activate EGFR by
increasing ectodomain shedding of HBEGF [161, 162]. Our study provides a novel aspect
of EGFR activation through the BHLHE40-HBEGF axis. In addition to autocrine or
paracrine effects within tumor cells, exosomic release of HBEGF might exert paracrine
effect to remodel tumor stroma or endocrine effect to prime distant metastatic niches
[163].
In conclusion, this study provides evidence supporting an essential role of
BHLHE40 in exosomic release of HBEGF, a critical pro-survival and pro-metastasis
factor. The clinical relevance of our findings is evidenced by the fact that the elevated
expression of BHLHE40 and HBEGF in breast tumors is associated with poor prognosis
of patients with TNBC and chemoresistance. Therapeutic intervention targeting the
BHLHE40-HBEGF axis may represent an effective approach to combat hypoxia-driven
drug resistance and metastasis.
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CHAPTER 4.

SUMMARY

When mammalian cells encounter hypoxia, they develop a variety of mechanisms
to cope with this stress and survive, as summarized in Table 4-1 [164]. Approximately 11.5% of the genome is transcriptionally responsive to hypoxia. However, there is
significant heterogeneity in the transcriptional response to hypoxia between different cell
types [165]. For instance, in the context of tumor cells, HIF1A can impart protumorigenic abilities by direct upregulation of targets like VEGF, LOX and MMP’s while
in the context of innate immunity, HIF1A can regulate T cells and lymphocytes to
promote inflammation by regulating the secretion of cytokines such as CCL5 and IL6
[166]. Therefore, strategies exploiting hypoxic response for therapy need to take into
consideration the cell context. This study identifies two HIF1A mediated pathways that
require the presence of other transcription regulators (i.e., SMARCE1 and BHLHE40) to
impart pro-metastatic abilities to breast cancer cells.
Low oxygen concentration of solid tumors has been linked to increased migratory
and invasive potential [19] a pre-requisite to metastatic breast cancer. HIF1A, master
controller of hypoxia, acts via multiple pathways to bestow on cancer cells pro-survival
and pro-metastatic abilities [167]. To develop strategies to prevent HIF1A-driven tumor
progression requires a detailed understanding of upstream regulators and downstream
effectors of HIF1A signaling pathways. Our results discover two downstream pathways,
HIF1A/SMARCE1-PTK2 and HIF1A-BHLHE40-HBEGF, that HIF1A exploits to impart
an increased metastatic potential to the breast cancer cells. Future studies are warranted to
evaluate the efficacy of strategies targeting HIF1A-SMARCE1 interaction, PTK2
activation and HBEGF secretion.
Key-findings
Key findings of this study are listed below (and represented in Figure 4-1).
•

Knockdown of EHMT2, SMARCA4, and KDM6B did not affect the metastatic
potential of MDA-MB-231 cells.

•

SMARCE1 knockdown does not affect the primary tumor growth but
significantly reduced spontaneous lung metastases in an orthotopic xenograft
model of breast cancer

•

SMARCE1 is required for HIF1A-mediated transactivation of PTK2 in response
to cell detachment. HIF1A/PTK2 pathway plays a key role in protecting
circulating tumor cells against anoikis.

•

BHLHE40 knockdown reduced both primary tumor burden and spontaneous lung
metastasis in-vivo
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Table 4-1.
expression.

Summary of epigenetic factors involved in hypoxia-regulated gene

Chromatin
modifiers
involved

Genes or proteins
regulated

Phenotypic changes

CITED1,
HDAC, PCAF,
Transcriptional coPPARGC1A,
regulators
PKM2, MCM,
FHL

Various hypoxiaresponsive genes, TP53,
HIF1A, BID, VEGF,
LDHA, PDK1,
SLC2A1, HK1

Angiogenesis, cell
cycle progression,
glycolytic pathway,
cell proliferation, and
other processes
regulated by hypoxia

Chromatinmodifying
complexes

HIF1A, SHBG, ITIH,
HIF1AN, BNIP3, CA9,
VEGF

Cell cycle arrest,
hematopoietic and
vascular development,
apoptosis, angiogenesis

EMT marker genes
(CDH1, JUP, CDH2,
VIM, etc.)

Migration, invasion,
metastasis

Category

SWI/SNF,
SMARCA4,
ISWI, MTA1

Chromatin
modifiers
HDAC3,
mediating hypoxia- WDR5
induced EMT

Hypoxia activated transcriptional co-regulators, chromatin modifying complexes, histone
modification enzymes and their role in tumor progression. Reprinted with permission
from Kou-Juey Wu, Epigenetic Regulation of hypoxia responsive gene expression:
Focusing on chromatin and DNA modifications. International Journal of Cancer, 2013,
Volume 134, Issue2.
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Figure 4-1.

Summary of results.

A. HIF1A modulates chromatin remodeling via the SMARCE1 subunit of the SWI/SNF
complex and the circadian cycle by direct transcriptional regulation of BHLHE40 leading
to tumor progression and metastasis. B. SMARCE1 regulates metastatic potential of
breast cancer cells by promoting survival of detached cells through the HIF1A/PTK2
pathway. C. HIF1A-BHLHE40 driven HBEGF activation potentates breast cancer cell
survival, invasion and metastasis.
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•

BHLHE40 functions as key downstream effector of HIF1A to regulate exosomal
secretion of HBEGF, which plays a key role in supporting cell migration and
survival.
SMARCE1: Implications in Other Cancers and Further Direction

Chromatin remodelers have been shown to play a role in tumor progression [167].
One of these important chromatin remodelers is the SWI/SNF nucleosome remodeling
complex also implicated in co-activation of HIF1A target genes [48]. SMARCE1/BAF57
is one of the subunits of this complex. Germline mutation in SMARCE1 predispose
young patients to both spinal and intracranial clear cell meningiomas (CCM) and studies
reveal heterozygous loss of function mutation in SMARCE1 to be causative of this tumor
[168]. This study warrants genetic sequencing of future cases of childhood CCM
including investigation of SMARCE1 gene [169] and such mutation screening can help
facilitate meningioma classification [170]. SMARCE1 also plays a role in regulating drug
response and cytokine secretion of ovarian cancer cells. siRNA mediated knockdown of
SMARCE1 was reported to increase cell cycle arrest in G1 when cells were treated with
anticancer drugs such as cisplatin, doxorubicin, paclitaxel and 5-fluorouracil [171].
Overexpression of SMARCE1 in SKOV3 ovarian cancer cells resulted in secretion of
IL8, MIP1B and RANTES chemokines, which are associated with CD8+ cytotoxic T-cell
infiltration. In addition, SMARCE1 has been shown to be a novel target to abrogate
androgen receptor-mediated gene activation in prostate cancer [172] [173].
Our study reveals a novel link of SMARCE1 to HIF1A-mediated breast cancer
metastasis. PTK2, a non-receptor tyrosine kinase is activated by integrin engagement and
growth factor stimulation. Following phosphorylation, PTK2 activates MAPK and AKT
pro-survival pathways [174]. PTK2 gene amplification has been reported in various
cancers and has been shown to aid in cancer initiation and cell survival. Recently, PTK2
activation has been shown to be required for Src-regulated CDH1 expression in colon
cancer cells and inhibition of PTK2 activity reduced cell invasion in these cells. In
addition, PTK2 overexpression can modulate ITGB1 to enhance EMT, invasion, and
metastasis of cancer cells to the lung [175]. Blocking PTK2 activation has been proven to
impair the migratory potential of breast cancer cells [176]. In this study, we identified a
novel mechanism of activation of PTK2 by HIF1A/SMARCE1 in breast cancer cell,
which contributes to HIF1A-mediated anoikis resistance.
Further studies are needed to identify other crucial SMARCE1 targets to facilitate
the development of SMARCE1-targeted therapy. Additional research should focus on
identifying other SWI/SNF accessory subunits involved in the hypoxic response and
delineate which domains of SMARCE1 are involved in HIF1A interaction.
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BHLHE40: Implications in Other Cancers and Further Direction
Deregulation of BHLHE40/DEC1 has been implicated in various types of
malignant carcinomas [177]. In human glioblastomas, BHLHE40 facilitates the metabolic
adaptability of cells to hypoxia stress by increasing glycolysis [178]. BHLHE40
expression is a poor prognostic marker in pancreatic cancer and modulates chemo
sensitivity to gemcitabine [179]. BHLHE40 was reported to be activated by TGFB in
colorectal cancer cells to invoke anti-apoptotic response by blocking the apoptotic
pathways initiated by mitochondria [180] [181]. Dominant negative mutants of
BHLHE40 were shown to prevent lung and liver metastasis of mammary carcinoma cell
lines JygMC(A) and 4T1 [182]. In pancreatic cancer, BHLHE40 activation by TGFB has
been shown to regulate EMT by regulating the expression of SMAD3, SNAIL, Caludin4, and N-cadherin [133]. Studies in human endometrial cancer cells, however, show that
BHLHE40 and BHLHE41 act to block EMT by suppressing TWIST1 expression through
competing with SP1 binding to DNA [183]. In addition, BHLHE40 has also been
implicated in regulation of cytokine secretion [71], and it plays a key role in production
of GM-CSF and IL-10 in T-cells [184]. Our results show that BHLHE40 is required for
exosomal secretion of HBEGF in response to HIF1A activation in breast cancer cells.
HBEGF, a ligand of EGFR, which plays a key role in promoting breast cancer cell
survival and migration [185].
Epidermal growth factor receptor belongs to a family of receptor tyrosine kinase
that is anchored in the cytoplasmic membrane and is activated by several ligands like
epidermal growth factor (EGF), TGFB, amphiregulin, and HBEGF. Upon activation,
EGFR causes activation of the MAPK/ ERK, AKT/PI3K, JNK, STAT’s and E2F family
of proteins that impart pro-survival capabilities to tumor cells. EGFR/MAPK/AKT
pathways have been often dysregulated in human cancers [186]. EGFR is overexpressed
in 50% of triple negative breast cancers (TNBC’s) and EGFR targeted therapies are being
used to enhance the initial sensitivity of TNBC cells to cytotoxic therapy [187]. Cotreatment of EGFR pathway inhibitors with PI3K/AKT pathway inhibitors enhanced the
anti-proliferative effects of EGFR inhibitors in MDA-MB-468 cells. Combinational
therapy of gefitinib and PI-103 reduced phosphorylation of AKT and MAPK and induced
caspase-dependent apoptosis in basal like breast cancer cells [188]. Recent studies have
also shown that EGFR signaling can enhance tumor invasion by upregulating MMP-9
expression and PTK2 phosphorylation in MDA-MB-231 and MCF-7 cells [189]. These
observations show the importance of EGFR activation in several steps of the metastatic
cascade [190-192].
While this study has produced some valuable insights into the role of BHLHE40
in cytokine release induced by HIF1A activation, there are two unanswered questions that
need to be addressed. First, the molecular mechanism underlying BHLHE40-mediated
transcription activation of HBEGF. Second, whether BHLHE40 plays a role in regulating
exosome assembly, transport and cargo loading. Probing for answers to these two
questions will facilitate investigation in the therapeutic potential of BHLHE40/HBEGF
pathway.
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